{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,8]],"date-time":"2026-11-08T04:05:29Z","timestamp":1794110729055,"version":"4.8.0"},"reference-count":321,"publisher":"Springer Science and Business Media LLC","issue":"9","license":[{"start":{"date-parts":[[2025,7,25]],"date-time":"2025-07-25T00:00:00Z","timestamp":1753401600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,7,25]],"date-time":"2025-07-25T00:00:00Z","timestamp":1753401600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Med Oncol"],"DOI":"10.1007\/s12032-025-02923-x","type":"journal-article","created":{"date-parts":[[2025,7,25]],"date-time":"2025-07-25T14:33:15Z","timestamp":1753453995000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":12,"title":["CAR T-cell therapy in hematologic and solid malignancies: mechanisms, clinical applications, and future directions"],"prefix":"10.1007","volume":"42","author":[{"given":"Anitha","family":"Kuttiappan","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Santenna","family":"Chenchula","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"K. Vishnu","family":"Vardhan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"R.","family":"Padmavathi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"T. Sri","family":"Varshini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lakshmi Sahitya","family":"Amerneni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Krishna Chaitanya","family":"Amerneni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Madhav Rao","family":"Chavan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,7,25]]},"reference":[{"key":"2923_CR1","doi-asserted-by":"publisher","first-page":"423","DOI":"10.1038\/nature22395","volume":"545","author":"M Sadelain","year":"2017","unstructured":"Sadelain M, Rivi\u00e8re I, Riddell S. Therapeutic T-cell engineering. Nature. 2017;545:423\u201331.","journal-title":"Nature"},{"key":"2923_CR2","doi-asserted-by":"publisher","first-page":"215","DOI":"10.1016\/j.coi.2009.02.009","volume":"21","author":"M Sadelain","year":"2009","unstructured":"Sadelain M, Brentjens R, Rivi\u00e8re I. The promise and potential pitfalls of chimeric antigen receptors. Curr Opin Immunol. 2009;21:215\u201323.","journal-title":"Curr Opin Immunol"},{"key":"2923_CR3","doi-asserted-by":"publisher","first-page":"483","DOI":"10.1158\/2326-6066.CIR-15-0048","volume":"3","author":"AJ Davenport","year":"2015","unstructured":"Davenport AJ, Jenkins MR, Cross RS, et al. CAR-T cells inflict sequential killing of multiple tumor target cells. Cancer Immunol Res. 2015;3:483\u201394.","journal-title":"Cancer Immunol Res"},{"key":"2923_CR4","doi-asserted-by":"publisher","first-page":"1435","DOI":"10.1002\/eji.1830230705","volume":"23","author":"T Brocker","year":"1993","unstructured":"Brocker T, Peter A, Traunecker A, Karjalainen K. New simplified molecular design for functional T-cell receptor. Eur J Immunol. 1993;23:1435\u20139.","journal-title":"Eur J Immunol"},{"key":"2923_CR5","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1038\/nrclinonc.2017.128","volume":"15","author":"JN Brudno","year":"2018","unstructured":"Brudno JN, Kochenderfer JN. Chimeric antigen receptor T-cell therapies for lymphoma. Nat Rev Clin Oncol. 2018;15:31\u201346.","journal-title":"Nat Rev Clin Oncol"},{"key":"2923_CR6","doi-asserted-by":"publisher","first-page":"1509","DOI":"10.1056\/NEJMoa1215134","volume":"368","author":"SA Grupp","year":"2013","unstructured":"Grupp SA, Kalos M, Barrett D, et al. Chimeric antigen receptor\u2013modified T cells for acute lymphoid leukemia. N Engl J Med. 2013;368:1509\u201318.","journal-title":"N Engl J Med"},{"key":"2923_CR7","doi-asserted-by":"publisher","first-page":"1570","DOI":"10.1182\/blood-2008-02-078071","volume":"112","author":"TW LeBien","year":"2008","unstructured":"LeBien TW, Tedder TF. B lymphocytes: how they develop and function. Blood. 2008;112:1570\u201380.","journal-title":"Blood"},{"key":"2923_CR8","doi-asserted-by":"publisher","first-page":"2545","DOI":"10.1056\/NEJMoa1708566","volume":"377","author":"SJ Schuster","year":"2017","unstructured":"Schuster SJ, Svoboda J, Chong EA, et al. Chimeric antigen receptor T cells in refractory B-cell lymphomas. N Engl J Med. 2017;377:2545\u201354.","journal-title":"N Engl J Med"},{"key":"2923_CR9","doi-asserted-by":"publisher","first-page":"1688","DOI":"10.1182\/blood-2016-04-711903","volume":"128","author":"SA Ali","year":"2016","unstructured":"Ali SA, Shi V, Maric I, et al. T cells expressing an anti-B-cell maturation antigen chimeric antigen receptor cause remissions of multiple myeloma. Blood. 2016;128:1688\u2013700.","journal-title":"Blood"},{"key":"2923_CR10","doi-asserted-by":"publisher","first-page":"279","DOI":"10.1038\/nm827","volume":"9","author":"RJ Brentjens","year":"2003","unstructured":"Brentjens RJ, Latouche JB, Santos E, et al. Eradication of systemic B-cell tumors by genetically targeted human T lymphocytes costimulated by CD80 and interleukin-15. Nat Med. 2003;9:279\u201386.","journal-title":"Nat Med"},{"key":"2923_CR11","doi-asserted-by":"publisher","first-page":"132ra53","DOI":"10.1126\/scitranslmed.3003761","volume":"4","author":"J Scholler","year":"2012","unstructured":"Scholler J, Brady T, Binder-Scholl G, et al. Decade-long safety and function of retroviral-modified chimeric antigen receptor T cells. Sci Transl Med. 2012;4:132ra53.","journal-title":"Sci Transl Med"},{"key":"2923_CR12","doi-asserted-by":"publisher","first-page":"90","DOI":"10.3390\/sci2040090","volume":"2","author":"DK Jarrell","year":"2020","unstructured":"Jarrell DK, Drake S, Brown MA. Advancing therapies for cancer\u2014from mustard gas to CAR T. Science. 2020;2:90. https:\/\/doi.org\/10.3390\/sci2040090.","journal-title":"Science"},{"key":"2923_CR13","doi-asserted-by":"publisher","first-page":"370","DOI":"10.1038\/nrclinonc.2016.36","volume":"13","author":"HJ Jackson","year":"2016","unstructured":"Jackson HJ, Rafiq S, Brentjens RJ. Driving CAR T cells forward. Nat Rev Clin Oncol. 2016;13:370\u201383. https:\/\/doi.org\/10.1038\/nrclinonc.2016.36.","journal-title":"Nat Rev Clin Oncol"},{"key":"2923_CR14","doi-asserted-by":"publisher","first-page":"960","DOI":"10.1016\/0006-291X(87)90502-X","volume":"149","author":"Y Kuwana","year":"1987","unstructured":"Kuwana Y, Asakura Y, Utsunomiya N, et al. Expression of chimeric receptor composed of immunoglobulin-derived V regions and T-cell receptor-derived C regions. Biochem Biophys Res Commun. 1987;149:960\u20138.","journal-title":"Biochem Biophys Res Commun"},{"key":"2923_CR15","doi-asserted-by":"publisher","first-page":"460","DOI":"10.1016\/j.jaip.2021.10.037","volume":"10","author":"J Wat","year":"2022","unstructured":"Wat J, Barmettler S. Hypogammaglobulinemia after chimeric antigen receptor (CAR) T-Cell therapy: characteristics, management, and future directions. J Allergy Clin Immunol Pract. 2022;10:460\u20136. https:\/\/doi.org\/10.1016\/j.jaip.2021.10.037.","journal-title":"J Allergy Clin Immunol Pract"},{"key":"2923_CR16","doi-asserted-by":"publisher","first-page":"259","DOI":"10.1177\/2515135520927164","volume":"8","author":"L Halim","year":"2020","unstructured":"Halim L, Maher J. CAR T-Cell immunotherapy of B-Cell malignancy: the story so far. Ther Adv Vaccines Immunother. 2020;8:259\u201361. https:\/\/doi.org\/10.1177\/2515135520927164.","journal-title":"Ther Adv Vaccines Immunother"},{"key":"2923_CR17","unstructured":"Golden D. Kymriah\u2019s 5-Year Survival Data Shows Promise of CAR T-Cell Therapy. [(accessed on 8 March 2023)]. Available online: https:\/\/acgtfoundation.org\/news\/kymriah-survival-data-shows-promise-of-car-t-cell-therapy\/"},{"key":"2923_CR18","doi-asserted-by":"publisher","DOI":"10.1016\/j.ebiom.2020.102931","volume":"58","author":"J Jayaraman","year":"2020","unstructured":"Jayaraman J, Mellody MP, Hou AJ, Desai RP, Fung AW, Pham AHT, Chen YY, Zhao W. CAR-T Design: elements and their synergistic function. EBioMedicine. 2020;58: 102931. https:\/\/doi.org\/10.1016\/j.ebiom.2020.102931.","journal-title":"EBioMedicine"},{"issue":"9","key":"2923_CR19","doi-asserted-by":"publisher","first-page":"3392","DOI":"10.1172\/JCI80010","volume":"125","author":"M Sadelain","year":"2015","unstructured":"Sadelain M. CAR therapy: the CD19 paradigm. J Clin Investig. 2015;125(9):3392\u2013400.","journal-title":"J Clin Investig"},{"key":"2923_CR20","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2022.876339","volume":"13","author":"N Watanabe","year":"2022","unstructured":"Watanabe N, Mo F, McKenna MK. Impact of manufacturing procedures on CAR T-Cell functionality. Front Immunol. 2022;13: 876339. https:\/\/doi.org\/10.3389\/fimmu.2022.876339.","journal-title":"Front Immunol"},{"issue":"1","key":"2923_CR21","doi-asserted-by":"publisher","first-page":"2","DOI":"10.2478\/ahp-2020-0002","volume":"51","author":"J Styczy\u0144ski","year":"2020","unstructured":"Styczy\u0144ski J. A brief history of CAR-T cells: from laboratory to the bedside. Acta Haematol Pol. 2020;51(1):2\u20135.","journal-title":"Acta Haematol Pol"},{"key":"2923_CR22","doi-asserted-by":"publisher","first-page":"342","DOI":"10.1038\/s41571-022-00607-3","volume":"19","author":"L Amini","year":"2022","unstructured":"Amini L, Silbert SK, Maude SL, Nastoupil LJ, Ramos CA, Brentjens RJ, Sauter CS, Shah NN, Abou-el-Enein M. Preparing for CAR T-Cell therapy: patient selection, bridging therapies and lymphodepletion. Nat Rev Clin Oncol. 2022;19:342\u201355. https:\/\/doi.org\/10.1038\/s41571-022-00607-3.","journal-title":"Nat Rev Clin Oncol"},{"key":"2923_CR23","doi-asserted-by":"publisher","first-page":"3321","DOI":"10.1182\/blood-2016-04-703751","volume":"127","author":"JN Brudno","year":"2016","unstructured":"Brudno JN, Kochenderfer JN. Toxicities of chimeric antigen receptor T cells: recognition and management. Blood. 2016;127:3321\u201330. https:\/\/doi.org\/10.1182\/blood-2016-04-703751.","journal-title":"Blood"},{"key":"2923_CR24","doi-asserted-by":"publisher","first-page":"540","DOI":"10.1200\/JCO.2014.56.2025","volume":"33","author":"JN Kochenderfer","year":"2015","unstructured":"Kochenderfer JN, Dudley ME, Kassim SH, et al. Chemotherapy-refractory diffuse large B-cell lymphoma and indolent B-cell malignancies can be effectively treated with autologous T cells expressing an anti-CD19 chimeric antigen receptor. J Clin Oncol. 2015;33:540\u20139.","journal-title":"J Clin Oncol"},{"issue":"6382","key":"2923_CR25","doi-asserted-by":"publisher","first-page":"1361","DOI":"10.1126\/science.aar6711","volume":"359","author":"CH June","year":"2018","unstructured":"June CH, O\u2019Connor RS, Kawalekar OU, et al. CAR T-cell immunotherapy for human cancer. Science. 2018;359(6382):1361\u20135.","journal-title":"Science"},{"issue":"12","key":"2923_CR26","doi-asserted-by":"publisher","first-page":"2501","DOI":"10.1016\/j.jid.2018.09.002","volume":"138","author":"HF Siddiqi","year":"2018","unstructured":"Siddiqi HF, Staser KW, Nambudiri VE. Research techniques made simple: CAR T-cell therapy. J Investigat Dermatol. 2018;138(12):2501\u20134.","journal-title":"J Investigat Dermatol"},{"key":"2923_CR27","doi-asserted-by":"publisher","first-page":"1653","DOI":"10.1084\/jem.181.5.1653","volume":"181","author":"T Brocker","year":"1995","unstructured":"Brocker T, Karjalainen K. Signals through T-cell receptor-zeta chain alone are insufficient to prime resting T lymphocytes. J Exp Med. 1995;181:1653\u20139.","journal-title":"J Exp Med"},{"key":"2923_CR28","doi-asserted-by":"publisher","first-page":"1283","DOI":"10.3390\/ijms20061283","volume":"20","author":"MR Benmebarek","year":"2019","unstructured":"Benmebarek MR, Karches CH, Cadilha BL, Lesch S, Endres S, Kobold S. Killing mechanisms of chimeric antigen receptor (CAR) T cells. Int J Mol Sci. 2019;20:1283. https:\/\/doi.org\/10.3390\/ijms20061283.","journal-title":"Int J Mol Sci"},{"key":"2923_CR29","doi-asserted-by":"publisher","first-page":"147","DOI":"10.1038\/s41571-019-0297-y","volume":"17","author":"S Rafiq","year":"2020","unstructured":"Rafiq S, Hackett CS, Brentjens RJ. Engineering strategies to overcome the current roadblocks in CAR T-Cell therapy. Nat Rev Clin Oncol. 2020;17:147\u201367. https:\/\/doi.org\/10.1038\/s41571-019-0297-y.","journal-title":"Nat Rev Clin Oncol"},{"issue":"11","key":"2923_CR30","doi-asserted-by":"publisher","first-page":"1595","DOI":"10.1001\/jamaoncol.2017.2989","volume":"3","author":"JM Pagel","year":"2017","unstructured":"Pagel JM, West HJ. Chimeric antigen receptor (CAR) T-cell therapy. JAMA oncol. 2017;3(11):1595.","journal-title":"JAMA oncol"},{"key":"2923_CR31","doi-asserted-by":"publisher","first-page":"70","DOI":"10.1038\/nbt0102-70","volume":"20","author":"J Maher","year":"2002","unstructured":"Maher J, Brentjens RJ, Gunset G, Rivi\u00e8re I, Sadelain M. Human T-lymphocyte cytotoxicity and proliferation directed by a single chimeric TCRzeta\/CD28 receptor. Nat Biotechnol. 2002;20:70\u20135.","journal-title":"Nat Biotechnol"},{"key":"2923_CR32","doi-asserted-by":"publisher","first-page":"1440","DOI":"10.1038\/nm1676","volume":"13","author":"MT Stephan","year":"2007","unstructured":"Stephan MT, Ponomarev V, Brentjens RJ, et al. T-cell-encoded CD80 and 4\u20131BBL induce auto and transcostimulation, resulting in potent tumor rejection. Nat Med. 2007;13:1440\u20139.","journal-title":"Nat Med"},{"key":"2923_CR33","doi-asserted-by":"publisher","first-page":"725","DOI":"10.1056\/NEJMoa1103849","volume":"365","author":"DL Porter","year":"2011","unstructured":"Porter DL, Levine BL, Kalos M, Bagg A, June CH. Chimeric antigen receptor-modified T cells in chronic lymphoid leukemia. N Engl J Med. 2011;365:725\u201333.","journal-title":"N Engl J Med"},{"key":"2923_CR34","doi-asserted-by":"publisher","first-page":"92","DOI":"10.1016\/j.omtm.2016.12.006","volume":"4","author":"BL Levine","year":"2017","unstructured":"Levine BL, Miskin J, Wonnacott K, Keir C. Global Manufacturing of CAR T-Cell Therapy. Mol Ther Methods Clin Dev. 2017;4:92\u2013101. https:\/\/doi.org\/10.1016\/j.omtm.2016.12.006.","journal-title":"Mol Ther Methods Clin Dev"},{"issue":"1","key":"2923_CR35","doi-asserted-by":"publisher","first-page":"107","DOI":"10.1111\/imr.12131","volume":"257","author":"G Dotti","year":"2014","unstructured":"Dotti G, Gottschalk S, Savoldo B, Brenner MK. Design and development of therapies using chimeric antigen receptor-expressing T cells. Immunol Rev. 2014;257(1):107\u201326.","journal-title":"Immunol Rev"},{"issue":"6332","key":"2923_CR36","doi-asserted-by":"publisher","first-page":"1428","DOI":"10.1126\/science.aaf1292","volume":"355","author":"E Hui","year":"2017","unstructured":"Hui E, Cheung J, Zhu J, Su X, Taylor MJ, Wallweber HA, et al. T-cell costimulatory receptor CD28 is a primary target for PD-1\u2013mediated inhibition. Science. 2017;355(6332):1428\u201333. https:\/\/doi.org\/10.1126\/science.aaf1292.","journal-title":"Science"},{"issue":"8","key":"2923_CR37","doi-asserted-by":"publisher","first-page":"494","DOI":"10.1016\/j.it.2015.06.004","volume":"36","author":"S Srivastava","year":"2015","unstructured":"Srivastava S, Riddell SR. Engineering CAR-T cells: design concepts. Trends Immunol. 2015;36(8):494\u2013502.","journal-title":"Trends Immunol"},{"key":"2923_CR38","doi-asserted-by":"publisher","first-page":"1341","DOI":"10.1038\/s41591-019-0564-6","volume":"25","author":"RG Majzner","year":"2019","unstructured":"Majzner RG, Mackall CL. Clinical lessons learned from the first leg of the CAR T-Cell journey. Nat Med. 2019;25:1341\u201355. https:\/\/doi.org\/10.1038\/s41591-019-0564-6.","journal-title":"Nat Med"},{"key":"2923_CR39","doi-asserted-by":"publisher","first-page":"2","DOI":"10.1126\/sciadv.aaz3223","volume":"6","author":"SE Lindner","year":"2020","unstructured":"Lindner SE, Johnson SM, Brown CE, Wang LD. Chimeric antigen receptor signaling: functional consequences and design implications. Sci Adv. 2020;6:2\u201310. https:\/\/doi.org\/10.1126\/sciadv.aaz3223.","journal-title":"Sci Adv"},{"key":"2923_CR40","doi-asserted-by":"publisher","first-page":"430","DOI":"10.1016\/j.molmed.2017.03.002","volume":"23","author":"ZL Chang","year":"2017","unstructured":"Chang ZL, Chen YY. CARs: synthetic immunoreceptors for cancer therapy and beyond. Trends Mol Med. 2017;23:430\u201350. https:\/\/doi.org\/10.1016\/j.molmed.2017.03.002.","journal-title":"Trends Mol Med"},{"key":"2923_CR41","doi-asserted-by":"publisher","first-page":"303ra139","DOI":"10.1126\/scitranslmed.aac5415","volume":"7","author":"DL Porter","year":"2015","unstructured":"Porter DL, Hwang WT, Frey NV, et al. Chimeric antigen receptor T cells persist and induce sustained remissions in relapsed refractory chronic lymphocytic leukemia. Sci Transl Med. 2015;7:303ra139.","journal-title":"Sci Transl Med"},{"key":"2923_CR42","unstructured":"Sangita Dey, Moodu Devender, Swati Rani, Rajan Kumar Pandey, Recent advances in CAR T-cell engineering using synthetic biology: Paving the way for next-generation cancer treatment, Advances in Protein Chemistry and Structural Biology, Academic Press, 2024."},{"key":"2923_CR43","doi-asserted-by":"publisher","first-page":"123","DOI":"10.1038\/sj.neo.7900018","volume":"1","author":"MC Gong","year":"1999","unstructured":"Gong MC, Latouche JB, Krause A, Heston WD, Bander NH, Sadelain M. Cancer patient T cells genetically targeted to prostate-specific membrane antigen specifically lyse prostate cancer cells and release cytokines in response to prostate-specific membrane antigen. Neoplasia. 1999;1:123\u20137.","journal-title":"Neoplasia"},{"key":"2923_CR44","doi-asserted-by":"publisher","first-page":"185","DOI":"10.1038\/s41573-019-0051-2","volume":"19","author":"S Depil","year":"2020","unstructured":"Depil S, Duchateau P, Grupp SA, Mufti G, Poirot L. \u2018Off-the-Shelf\u2019\u2019 allogeneic CAR T cells: development and challenges. Nat Rev Drug Discov. 2020;19:185\u201399. https:\/\/doi.org\/10.1038\/s41573-019-0051-2.","journal-title":"Nat Rev Drug Discov"},{"key":"2923_CR45","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2021.780442","volume":"12","author":"PH Mehta","year":"2021","unstructured":"Mehta PH, Fiorenza S, Koldej RM, Jaworowski A, Ritchie DS, Quinn KM. T-Cell fitness and autologous CAR T-Cell therapy in haematologic malignancy. Front Immunol. 2021;12: 780442. https:\/\/doi.org\/10.3389\/fimmu.2021.780442.","journal-title":"Front Immunol"},{"issue":"53","key":"2923_CR46","doi-asserted-by":"publisher","first-page":"164","DOI":"10.1016\/j.copbio.2018.01.025","volume":"1","author":"P Vormittag","year":"2018","unstructured":"Vormittag P, Gunn R, Ghorashian S, Veraitch FS. A guide to manufacturing CAR T-cell therapies. Curr Opin Biotechnol. 2018;1(53):164\u201381.","journal-title":"Curr Opin Biotechnol"},{"issue":"12","key":"2923_CR47","doi-asserted-by":"publisher","first-page":"683","DOI":"10.1159\/000442170","volume":"38","author":"BC Miller","year":"2015","unstructured":"Miller BC, Maus MV. CD19-targeted CAR T cells: a new tool in the fight against B-cell malignancies. Oncol Res Treat. 2015;38(12):683\u201390.","journal-title":"Oncol Res Treat"},{"key":"2923_CR48","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s40425-019-0686-x","volume":"7","author":"R Lemal","year":"2019","unstructured":"Lemal R, Tournilhac O. State-of-the-art for CAR T-cell therapy for chronic lymphocytic leukemia in 2019. J Immunother Cancer. 2019;7:1\u20136.","journal-title":"J Immunother Cancer"},{"issue":"12","key":"2923_CR49","doi-asserted-by":"publisher","first-page":"4303","DOI":"10.3390\/ijms21124303","volume":"21","author":"A Ahmad","year":"2020","unstructured":"Ahmad A. CAR-T-cell therapy. Int J Mol Sci. 2020;21(12):4303.","journal-title":"Int J Mol Sci"},{"key":"2923_CR50","doi-asserted-by":"publisher","first-page":"3025","DOI":"10.1016\/j.celrep.2017.09.002","volume":"20","author":"B Hu","year":"2017","unstructured":"Hu B, Ren J, Luo Y, et al. Augmentation of antitumour immunity by human and mouse CAR T cells secreting IL-18. Cell Rep. 2017;20:3025\u201333.","journal-title":"Cell Rep"},{"issue":"10","key":"2923_CR51","doi-asserted-by":"publisher","first-page":"3079","DOI":"10.1111\/cas.14169","volume":"110","author":"M Nakajima","year":"2019","unstructured":"Nakajima M, Sakoda Y, Adachi K, Nagano H, Tamada K. Improved survival of chimeric antigen receptor-engineered T (CAR-T) and tumor-specific T cells caused by anti-programmed cell death protein 1 single-chain variable fragment-producing CAR-T cells. Cancer Sci. 2019;110(10):3079\u201388.","journal-title":"Cancer Sci"},{"issue":"34","key":"2923_CR52","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1016\/j.blre.2018.11.002","volume":"1","author":"JN Brudno","year":"2019","unstructured":"Brudno JN, Kochenderfer JN. Recent advances in CAR T-cell toxicity: mechanisms, manifestations and management. Blood Rev. 2019;1(34):45\u201355.","journal-title":"Blood Rev"},{"key":"2923_CR53","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2021.744823","volume":"12","author":"H Lin","year":"2021","unstructured":"Lin H, Cheng J, Mu W, Zhou J, Zhu L. Advances in universal CAR-T-Cell therapy. Front Immunol. 2021;12: 744823. https:\/\/doi.org\/10.3389\/fimmu.2021.744823.","journal-title":"Front Immunol"},{"key":"2923_CR54","doi-asserted-by":"publisher","first-page":"128","DOI":"10.1186\/s13045-019-0813-7","volume":"12","author":"X Han","year":"2019","unstructured":"Han X, Wang Y, Wei J, Han W. Multi-antigen-targeted chimeric antigen receptor T cells for cancer therapy. J Hematol Oncol. 2019;12:128. https:\/\/doi.org\/10.1186\/s13045-019-0813-7.","journal-title":"J Hematol Oncol"},{"key":"2923_CR55","doi-asserted-by":"publisher","first-page":"377","DOI":"10.1038\/s41551-018-0235-9","volume":"2","author":"L Labanieh","year":"2018","unstructured":"Labanieh L, Majzner RG, Mackall CL. Programming CAR-T cells to kill cancer. Nat Biomed Eng. 2018;2:377\u201391. https:\/\/doi.org\/10.1038\/s41551-018-0235-9.","journal-title":"Nat Biomed Eng"},{"key":"2923_CR56","doi-asserted-by":"publisher","first-page":"379","DOI":"10.1038\/s41571-021-00476-2","volume":"18","author":"DL Wagner","year":"2021","unstructured":"Wagner DL, Fritsche E, Pulsipher MA, Ahmed N, Hamieh M, Hegde M, Ruella M, Savoldo B, Shah NN, Turtle CJ, et al. Immunogenicity of CAR T cells in cancer therapy. Nat Rev Clin Oncol. 2021;18:379\u201393. https:\/\/doi.org\/10.1038\/s41571-021-00476-2.","journal-title":"Nat Rev Clin Oncol"},{"key":"2923_CR57","doi-asserted-by":"publisher","first-page":"7222","DOI":"10.3390\/ijms21197222","volume":"21","author":"AR Sutherland","year":"2020","unstructured":"Sutherland AR, Owens MN, Geyer CR. Modular chimeric antigen receptor systems for universal CAR T-Cell retargeting. Int J Mol Sci. 2020;21:7222. https:\/\/doi.org\/10.3390\/ijms21197222.","journal-title":"Int J Mol Sci"},{"key":"2923_CR58","doi-asserted-by":"publisher","first-page":"1803","DOI":"10.1200\/JCO.2016.71.3024","volume":"35","author":"JN Kochenderfer","year":"2017","unstructured":"Kochenderfer JN, Somerville RPT, Lu T, Shi V, Bot A, Rossi J, Xue A, Goff SL, Yang JC, Sherry RM, et al. Lymphoma remissions caused by Anti-CD19 chimeric antigen receptor T cells are associated with high serum interleukin-15 levels. J Clin Oncol. 2017;35:1803\u201313. https:\/\/doi.org\/10.1200\/JCO.2016.71.3024.","journal-title":"J Clin Oncol"},{"key":"2923_CR59","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s13045-017-0423-1","volume":"10","author":"Z Wang","year":"2017","unstructured":"Wang Z, Wu Z, Liu Y, Han W. New development in CAR-T-cell therapy. J Hematol Oncol. 2017;10:1\u20131.","journal-title":"J Hematol Oncol"},{"key":"2923_CR60","doi-asserted-by":"publisher","first-page":"4901","DOI":"10.4049\/jimmunol.180.7.4901","volume":"180","author":"S Wilkie","year":"2008","unstructured":"Wilkie S, Picco G, Foster J, Davies DM, Julien S, Cooper L, Arif S, Mather SJ, Taylor-Papadimitriou J, Burchell JM, et al. Retargeting of human T cells to tumor-associated MUC1: the evolution of a chimeric antigen receptor. J Immunol. 2008;180:4901\u20139. https:\/\/doi.org\/10.4049\/jimmunol.180.7.4901.","journal-title":"J Immunol"},{"key":"2923_CR61","doi-asserted-by":"publisher","first-page":"1943","DOI":"10.1038\/s41375-022-01585-2","volume":"36","author":"ML Olson","year":"2022","unstructured":"Olson ML, Mause ERV, Radhakrishnan SV, Brody JD, Rapoport AP, Welm AL, Atanackovic D, Luetkens T. Low-Affinity CAR T cells exhibit reduced trogocytosis, preventing rapid antigen loss, and increasing CAR T-Cell expansion. Leukemia. 2022;36:1943\u20136. https:\/\/doi.org\/10.1038\/s41375-022-01585-2.","journal-title":"Leukemia"},{"issue":"1","key":"2923_CR62","first-page":"5474602","volume":"2016","author":"H Alm\u00e5sbak","year":"2016","unstructured":"Alm\u00e5sbak H, Aarvak T, Vemuri MC. CAR T-cell therapy: a game changer in cancer treatment. J Immunol Res. 2016;2016(1):5474602.","journal-title":"J Immunol Res"},{"key":"2923_CR63","doi-asserted-by":"publisher","first-page":"901","DOI":"10.1016\/S0092-8674(02)00799-7","volume":"109","author":"D Gil","year":"2002","unstructured":"Gil D, Schamel WWA, Montoya M, S\u00e1nchez-Madrid F, Alarc\u00f3n B. Recruitment of Nck by CD3\u03b5 reveals a ligand- induced conformational change essential for T-Cell receptor signaling and synapse formation. Cell. 2002;109:901\u201312. https:\/\/doi.org\/10.1016\/S0092-8674(02)00799-7.","journal-title":"Cell"},{"key":"2923_CR64","doi-asserted-by":"publisher","first-page":"1054","DOI":"10.1016\/j.jaad.2016.06.062","volume":"75","author":"CB Rubin","year":"2016","unstructured":"Rubin CB, Elenitsas R, Taylor L, et al. Evaluating the skin in patients undergoing chimeric antigen receptor modified T-cell therapy. J Am Acad Dermatol. 2016;75:1054\u20137.","journal-title":"J Am Acad Dermatol"},{"key":"2923_CR65","doi-asserted-by":"publisher","first-page":"4262","DOI":"10.1172\/JCI84813","volume":"126","author":"PJ Paszkiewicz","year":"2016","unstructured":"Paszkiewicz PJ, Fr\u00e4\u00dfle SP, Srivastava S, et al. Targeted antibody-mediated depletion of murine CD19 CAR T cells permanently reverses B-cell aplasia. J Clin Invest. 2016;126:4262\u201372.","journal-title":"J Clin Invest"},{"issue":"56","key":"2923_CR66","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1146\/annurev-pharmtox-010814-124844","volume":"6","author":"G Gross","year":"2016","unstructured":"Gross G, Eshhar Z. Therapeutic potential of T-cell chimeric antigen receptors (CARs) in cancer treatment: counteracting off-tumor toxicities for safe CAR T-cell therapy. Annu Rev Pharmacol Toxicol. 2016;6(56):59\u201383.","journal-title":"Annu Rev Pharmacol Toxicol"},{"issue":"9","key":"2923_CR67","doi-asserted-by":"publisher","first-page":"634","DOI":"10.1007\/s13238-017-0410-x","volume":"8","author":"J Ren","year":"2017","unstructured":"Ren J, Zhao Y. Advancing chimeric antigen receptor T-cell therapy with CRISPR\/Cas9. Protein Cell. 2017;8(9):634\u201343.","journal-title":"Protein Cell"},{"issue":"7","key":"2923_CR68","doi-asserted-by":"publisher","first-page":"1561","DOI":"10.4049\/jimmunol.2001249","volume":"206","author":"VE Tedesco","year":"2021","unstructured":"Tedesco VE, Mohan C. Biomarkers for predicting cytokine release syndrome following CD19-targeted CAR T-cell therapy. J Immunol. 2021;206(7):1561\u20138.","journal-title":"J Immunol"},{"issue":"9","key":"2923_CR69","doi-asserted-by":"publisher","first-page":"1985","DOI":"10.1111\/ajt.12834","volume":"14","author":"D Gardner","year":"2014","unstructured":"Gardner D, Jeffery LE, Sansom DM. Understanding the CD28\/CTLA-4 (CD152) pathway and its implications for costimulatory blockade. Am J Transplant. 2014;14(9):1985\u201391. https:\/\/doi.org\/10.1111\/ajt.12834.","journal-title":"Am J Transplant"},{"issue":"11","key":"2923_CR70","doi-asserted-by":"publisher","first-page":"2623","DOI":"10.1038\/sj.emboj.7601146","volume":"25","author":"R Nurieva","year":"2006","unstructured":"Nurieva R, Thomas S, Nguyen T, Martin-Orozco N, Wang Y, Kaja MK, et al. T-cell tolerance or function is determined by combinatorial costimulatory signals. EMBO J. 2006;25(11):2623\u201333. https:\/\/doi.org\/10.1038\/sj.emboj.7601146.","journal-title":"EMBO J"},{"key":"2923_CR71","doi-asserted-by":"publisher","first-page":"36","DOI":"10.1186\/2162-3619-1-36","volume":"1","author":"K Wang","year":"2012","unstructured":"Wang K, Wei G, Liu D. CD19: a biomarker for B-Cell development, lymphoma diagnosis and therapy. Exp Hematol Oncol. 2012;1:36. https:\/\/doi.org\/10.1186\/2162-3619-1-36.","journal-title":"Exp Hematol Oncol"},{"issue":"6","key":"2923_CR72","first-page":"2183","volume":"42","author":"R Mohanty","year":"2019","unstructured":"Mohanty R, Chowdhury CR, Arega S, Sen P, Ganguly P, Ganguly N. CAR T-cell therapy: a new era for cancer treatment. Oncol Rep. 2019;42(6):2183\u201395.","journal-title":"Oncol Rep"},{"key":"2923_CR73","doi-asserted-by":"publisher","first-page":"1507","DOI":"10.1056\/NEJMoa1407222","volume":"371","author":"SL Maude","year":"2014","unstructured":"Maude SL, Frey N, Shaw PA, Aplenc R, Barrett DM, Bunin NJ, Chew A, Gonzalez VE, Zheng Z, Lacey SF, et al. Chimeric antigen receptor T Cells for sustained remissions in leukemia. N Engl J Med. 2014;371:1507\u201317. https:\/\/doi.org\/10.1056\/NEJMoa1407222.","journal-title":"N Engl J Med"},{"key":"2923_CR74","doi-asserted-by":"publisher","first-page":"1593","DOI":"10.2217\/fon-2017-0102","volume":"13","author":"B Demoulin","year":"2017","unstructured":"Demoulin B, Cook WJ, Murad J, Graber DJ, Sentman ML, Lonez C, Gilham DE, Sentman CL, Agaugue S. Exploiting natural killer group 2D receptors for CAR T-Cell therapy. Futur Oncol. 2017;13:1593\u2013605. https:\/\/doi.org\/10.2217\/fon-2017-0102.","journal-title":"Futur Oncol"},{"key":"2923_CR75","doi-asserted-by":"crossref","unstructured":"Fan F, Zhao WH, Liu J, et al.\u00a0Durable remissions with BCMA-specific chimeric antigen receptor (CAR)-modified T cells in patients with refractory\/relapsed mulple myeloma. J Clin Oncol\u00a02017. (Epub ahead of print).","DOI":"10.1200\/JCO.2017.35.18_suppl.LBA3001"},{"issue":"Suppl","key":"2923_CR76","doi-asserted-by":"publisher","first-page":"3010","DOI":"10.1200\/JCO.2017.35.15_suppl.3010","volume":"35","author":"JG Berdeja","year":"2017","unstructured":"Berdeja JG, Lin Y, Raje NS, et al. First-in-human multicenter study of bb2121 anti-BCMA CAR T-cell therapy for relapsed\/refractory multiple myeloma: updated results. J Clin Oncol. 2017;35(Suppl):3010.","journal-title":"J Clin Oncol"},{"issue":"6","key":"2923_CR77","first-page":"372","volume":"16","author":"NN Shah","year":"2019","unstructured":"Shah NN, Fry TJ. Mechanisms of resistance to CAR T-cell therapy. Nat Rev Clin Oncol. 2019;16(6):372\u201385.","journal-title":"Nat Rev Clin Oncol"},{"key":"2923_CR78","doi-asserted-by":"publisher","first-page":"2535","DOI":"10.1200\/JCO.2019.37.15_suppl.2535","volume":"37","author":"L Han","year":"2019","unstructured":"Han L, Gao Q, Zhou K, Zhou J, Fang B, Zhang J, Li H, Song Y. The Phase I clinical study of CART targeting BCMA with humanized alpaca-derived single-domain antibody as antigen recognition domain. J Clin Oncol. 2019;37:2535. https:\/\/doi.org\/10.1200\/JCO.2019.37.15_suppl.2535.","journal-title":"J Clin Oncol"},{"key":"2923_CR79","doi-asserted-by":"publisher","first-page":"619","DOI":"10.1084\/jem.188.4.619","volume":"188","author":"A Krause","year":"1998","unstructured":"Krause A, Guo HF, Latouche JB, Tan C, Cheung NK, Sadelain M. Antigen-dependent CD28 signaling selectively enhances survival and proliferation in genetically modified activated human primary T lymphocytes. J Exp Med. 1998;188:619\u201326.","journal-title":"J Exp Med"},{"key":"2923_CR80","doi-asserted-by":"publisher","first-page":"2561","DOI":"10.1056\/NEJMoa1610497","volume":"375","author":"CE Brown","year":"2016","unstructured":"Brown CE, Alizadeh D, Starr R, et al. Regression of glioblastoma after chimeric antigen receptor T-cell therapy. N Engl J Med. 2016;375:2561\u20139.","journal-title":"N Engl J Med"},{"issue":"4","key":"2923_CR81","doi-asserted-by":"publisher","first-page":"415","DOI":"10.1016\/j.ccell.2015.09.004","volume":"28","author":"Z Zhao","year":"2015","unstructured":"Zhao Z, Condomines M, van der Stegen SJ, Perna F, Kloss CC, Gunset G, Plotkin J, Sadelain M. Structural design of engineered costimulation determines tumor rejection kinetics and persistence of CAR T cells. Cancer Cell. 2015;28(4):415\u201328.","journal-title":"Cancer Cell"},{"issue":"1","key":"2923_CR82","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1038\/ni.1679","volume":"10","author":"SD Blackburn","year":"2009","unstructured":"Blackburn SD, Shin H, Haining WN, Zou T, Workman CJ, Polley A, et al. Coregulation of CD8+ T-cell exhaustion by multiple inhibitory receptors during chronic viral infection. Nat Immunol. 2009;10(1):29\u201337. https:\/\/doi.org\/10.1038\/ni.1679.","journal-title":"Nat Immunol"},{"key":"2923_CR83","doi-asserted-by":"publisher","first-page":"540","DOI":"10.1200\/JCO.2014.56.2025","volume":"33","author":"JN Kochenderfer","year":"2015","unstructured":"Kochenderfer JN, Dudley ME, Kassim SH, Somerville RPT, Carpenter RO, Maryalice SS, Yang JC, Phan GQ, Hughes MS, Sherry RM, et al. Chemotherapy-refractory diffuse large B-Cell lymphoma and indolent B-Cell malignancies can be effectively treated with Autologous T Cells expressing an Anti-CD19 chimeric antigen receptor. J Clin Oncol. 2015;33:540\u20139. https:\/\/doi.org\/10.1200\/JCO.2014.56.2025.","journal-title":"J Clin Oncol"},{"issue":"1","key":"2923_CR84","doi-asserted-by":"publisher","first-page":"119","DOI":"10.1186\/s13046-022-02327-z","volume":"41","author":"K Pan","year":"2022","unstructured":"Pan K, Farrukh H, Chittepu VC, Xu H, Pan CX, Zhu Z. CAR race to cancer immunotherapy: from CAR T, CAR NK to CAR macrophage therapy. J Exp Clin Cancer Res. 2022;41(1):119.","journal-title":"J Exp Clin Cancer Res"},{"key":"2923_CR85","doi-asserted-by":"publisher","first-page":"1563","DOI":"10.1007\/s00262-013-1459-x","volume":"62","author":"A Casati","year":"2013","unstructured":"Casati A, Varghaei-Nahvi A, Feldman SA, Assenmacher M, Rosenberg SA, Dudley ME, Scheffold A. Clinical-scale selection and viral transduction of human na\u00efve and central memory CD8+ T Cells for adoptive cell therapy of cancer patients. Cancer Immunol Immunother. 2013;62:1563\u201373. https:\/\/doi.org\/10.1007\/s00262-013-1459-x.","journal-title":"Cancer Immunol Immunother"},{"key":"2923_CR86","doi-asserted-by":"publisher","first-page":"715","DOI":"10.1038\/s41571-021-00530-z","volume":"18","author":"KM Cappell","year":"2021","unstructured":"Cappell KM, Kochenderfer JN. A comparison of chimeric antigen receptors containing CD28 versus 4\u20131BB costimulatory domains. Nat Rev Clin Oncol. 2021;18:715\u201327. https:\/\/doi.org\/10.1038\/s41571-021-00530-z.","journal-title":"Nat Rev Clin Oncol"},{"key":"2923_CR87","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1038\/s41571-022-00704-3","volume":"20","author":"CL Flugel","year":"2022","unstructured":"Flugel CL, Majzner RG, Krenciute G, Dotti G, Riddell SR, Wagner DL, Abou-el-Enein M. Overcoming on-target, off-tumour toxicity of CAR T-Cell therapy for solid tumors. Nat Rev Clin Oncol. 2022;20:49\u201362. https:\/\/doi.org\/10.1038\/s41571-022-00704-3.","journal-title":"Nat Rev Clin Oncol"},{"key":"2923_CR88","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1016\/j.omto.2022.03.009","volume":"25","author":"LA Kankeu Fonkoua","year":"2022","unstructured":"Kankeu Fonkoua LA, Sirpilla O, Sakemura R, Siegler EL, Kenderian SSCAR. T-Cell therapy and the tumor microenvironment: current challenges and opportunities. Mol Ther Oncolyt. 2022;25:69\u201377. https:\/\/doi.org\/10.1016\/j.omto.2022.03.009.","journal-title":"Mol Ther Oncolyt"},{"issue":"21","key":"2923_CR89","doi-asserted-by":"publisher","first-page":"9543","DOI":"10.1128\/MCB.25.21.9543-9553.2005","volume":"25","author":"RV Parry","year":"2005","unstructured":"Parry RV, Chemnitz JM, Frauwirth KA, Lanfranco AR, Braunstein I, Kobayashi SV, et al. CTLA-4 and PD-1 receptors inhibit T-cell activation by distinct mechanisms. Mol Cell Biol. 2005;25(21):9543\u201353. https:\/\/doi.org\/10.1128\/MCB.25.21.9543-9553.2005.","journal-title":"Mol Cell Biol"},{"issue":"7","key":"2923_CR90","doi-asserted-by":"publisher","first-page":"1027","DOI":"10.1084\/jem.192.7.1027","volume":"192","author":"GJ Freeman","year":"2000","unstructured":"Freeman GJ, Long AJ, Iwai Y, Bourque K, Chernova T, Nishimura H, et al. Engagement of the Pd-1 immunoinhibitory receptor by a novel B7 family member leads to negative regulation of lymphocyte activation. J Exp Med. 2000;192(7):1027\u201334. https:\/\/doi.org\/10.1084\/jem.192.7.1027.","journal-title":"J Exp Med"},{"key":"2923_CR91","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1007\/82_2010_116","volume":"350","author":"HT Jin","year":"2011","unstructured":"Jin HT, Ahmed R, Okazaki T. Role of PD-1 in regulating T-cell immunity. Curr Top Microbiol Immunol. 2011;350:17\u201337. https:\/\/doi.org\/10.1007\/82_2010_116.","journal-title":"Curr Top Microbiol Immunol"},{"issue":"4","key":"2923_CR92","first-page":"621","volume":"11","author":"D Darowski","year":"2019","unstructured":"Darowski D, Kobold S, Jost C, Klein C. Combining the best of two worlds: highly flexible chimeric antigen receptor adaptor molecules (CAR-adaptors) for the recruitment of chimeric antigen receptor T cells. InMAbs. 2019;11(4):621\u201331.","journal-title":"InMAbs"},{"key":"2923_CR93","doi-asserted-by":"publisher","first-page":"6644685","DOI":"10.1155\/2021\/6644685","volume":"2021","author":"V Lukjanov","year":"2021","unstructured":"Lukjanov V, Koutn\u00e1 I, \u0160imara P. CAR T-Cell production using nonviral approaches. J Immunol Res. 2021;2021:6644685. https:\/\/doi.org\/10.1155\/2021\/6644685.","journal-title":"J Immunol Res"},{"issue":"2","key":"2923_CR94","doi-asserted-by":"publisher","first-page":"227","DOI":"10.1016\/j.immuni.2015.06.018","volume":"43","author":"MS Lee","year":"2015","unstructured":"Lee MS, Glassman CR, Deshpande NR, Badgandi HB, Parrish HL, Uttamapinant C, Stawski PS, Ting AY, Kuhns MS. A mechanical switch couples T cell receptor triggering to the cytoplasmic juxtamembrane regions of CD3\u03b6\u03b6. Immunity. 2015;43(2):227\u201339. https:\/\/doi.org\/10.1016\/j.immuni.2015.06.018.","journal-title":"Immunity"},{"key":"2923_CR95","doi-asserted-by":"publisher","first-page":"412","DOI":"10.1038\/s41392-021-00823-w","volume":"6","author":"K Shah","year":"2021","unstructured":"Shah K, Al-Haidari A, Sun J, Kazi JU. T-Cell Receptor (TCR) signaling in health and disease. Signal Transduct Target Ther. 2021;6:412. https:\/\/doi.org\/10.1038\/s41392-021-00823-w.","journal-title":"Signal Transduct Target Ther"},{"key":"2923_CR96","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2022.886546","volume":"13","author":"AN Khan","year":"2022","unstructured":"Khan AN, Chowdhury A, Karulkar A, Jaiswal AK, Banik A, Asija S, Purwar R. Immunogenicity of CAR-T-Cell therapeutics: evidence. Mech Mitigat Front Immunol. 2022;13: 886546. https:\/\/doi.org\/10.3389\/fimmu.2022.886546.","journal-title":"Mech Mitigat Front Immunol"},{"issue":"5","key":"2923_CR97","doi-asserted-by":"publisher","first-page":"765","DOI":"10.1093\/intimm\/8.5.765","volume":"8","author":"Y Agata","year":"1996","unstructured":"Agata Y, Kawasaki A, Nishimura H, Ishida Y, Tsubat T, Yagita H, et al. Expression of the PD-1 antigen on the surface of stimulated mouse T and B lymphocytes. Int Immunol. 1996;8(5):765\u201372. https:\/\/doi.org\/10.1093\/intimm\/8.5.765.","journal-title":"Int Immunol"},{"issue":"230","key":"2923_CR98","doi-asserted-by":"publisher","first-page":"ra46","DOI":"10.1126\/scisignal.2002796","volume":"5","author":"N Patsoukis","year":"2012","unstructured":"Patsoukis N, Brown J, Petkova V, Liu F, Li L, Boussiotis VA. Selective effects of PD-1 on Akt and Ras pathways regulate molecular components of the cell cycle and inhibit T-cell proliferation. Sci Signal. 2012;5(230):ra46-46. https:\/\/doi.org\/10.1126\/scisignal.2002796.","journal-title":"Sci Signal"},{"issue":"2","key":"2923_CR99","doi-asserted-by":"publisher","first-page":"945","DOI":"10.4049\/jimmunol.173.2.945","volume":"173","author":"JM Chemnitz","year":"2004","unstructured":"Chemnitz JM, Parry RV, Nichols KE, June CH, Riley JL. SHP-1 and SHP-2 associate with immunoreceptor tyrosine-based switch motif of programmed death 1 upon primary human T-cell stimulation, but only receptor ligation prevents T-cell activation. J Immunol. 2004;173(2):945\u201354. https:\/\/doi.org\/10.4049\/jimmunol.173.2.945.","journal-title":"J Immunol"},{"issue":"1\u20133","key":"2923_CR100","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1016\/j.febslet.2004.07.083","volume":"574","author":"K-A Sheppard","year":"2004","unstructured":"Sheppard K-A, Fitz LJ, Lee JM, Benander C, George JA, Wooters J, et al. PD-1 inhibits T-cell receptor induced phosphorylation of the ZAP70\/CD3\u03b6 signalosome and downstream signaling to PKC\u03b8. FEBS Lett. 2004;574(1\u20133):37\u201341. https:\/\/doi.org\/10.1016\/j.febslet.2004.07.083.","journal-title":"FEBS Lett"},{"issue":"6","key":"2923_CR101","doi-asserted-by":"publisher","first-page":"492","DOI":"10.1046\/j.1399-0039.2003.00136.x","volume":"62","author":"C Nielsen","year":"2003","unstructured":"Nielsen C, Hansen D, Husby S, Jacobsen BB, Lillevang ST. Association of a putative regulatory polymorphism in the PD-1 gene with susceptibility to type 1 diabetes. Tissue Antigens. 2003;62(6):492\u20137. https:\/\/doi.org\/10.1046\/j.1399-0039.2003.00136.x.","journal-title":"Tissue Antigens"},{"issue":"3","key":"2923_CR102","doi-asserted-by":"publisher","first-page":"634","DOI":"10.1002\/1521-4141(200203)32:3<634:AID-IMMU634>3.0.CO;2-9","volume":"32","author":"L Carter","year":"2002","unstructured":"Carter L, Fouser LA, Jussif J, Fitz L, Deng B, Wood CR. PD-1:PD-L inhibitory pathway affects both CD4+ and CD8+ T cells and is overcome by IL-2. Eur J Immunol. 2002;32(3):634\u201343. https:\/\/doi.org\/10.1002\/1521-4141(200203)32:3%3c634:AID-IMMU634%3e3.0.CO;2-9.","journal-title":"Eur J Immunol"},{"issue":"10","key":"2923_CR103","doi-asserted-by":"publisher","first-page":"1563","DOI":"10.1093\/intimm\/10.10.1563","volume":"10","author":"H Nishimura","year":"1998","unstructured":"Nishimura H, Minato N, Nakano T, Honjo T. Immunological studies on PD-1 deficient mice: implication of PD-1 as a negative regulator for B-cell responses. Int Immunol. 1998;10(10):1563\u201372. https:\/\/doi.org\/10.1093\/intimm\/10.10.1563.","journal-title":"Int Immunol"},{"issue":"1","key":"2923_CR104","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1084\/jem.20022119","volume":"198","author":"AD Salama","year":"2003","unstructured":"Salama AD, Chitnis T, Imitola J, Ansari MJ, Akiba H, Tushima F, et al. Critical role of the programmed death-1 (PD-1) pathway in regulation of experimental autoimmune encephalomyelitis. J Exp Med. 2003;198(1):71\u20138. https:\/\/doi.org\/10.1084\/jem.20022119.","journal-title":"J Exp Med"},{"issue":"65","key":"2923_CR105","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1016\/j.copbio.2020.01.009","volume":"1","author":"E Lanitis","year":"2020","unstructured":"Lanitis E, Coukos G, Irving M. All systems go: converging synthetic biology and combinatorial treatment for CAR-T-cell therapy. Curr Opin Biotechnol. 2020;1(65):75\u201387.","journal-title":"Curr Opin Biotechnol"},{"key":"2923_CR106","doi-asserted-by":"publisher","first-page":"325","DOI":"10.1038\/s41569-019-0164-7","volume":"16","author":"KH Simons","year":"2019","unstructured":"Simons KH, de Jong A, Jukema JW, de Vries MR, Arens R, Quax PHA. T-Cell co-stimulation and co-inhibition in cardiovascular disease: a double-edged sword. Nat Rev Cardiol. 2019;16:325\u201343. https:\/\/doi.org\/10.1038\/s41569-019-0164-7.","journal-title":"Nat Rev Cardiol"},{"issue":"7","key":"2923_CR107","doi-asserted-by":"publisher","first-page":"531","DOI":"10.1038\/s41573-021-00189-2","volume":"20","author":"AJ Hou","year":"2021","unstructured":"Hou AJ, Chen LC, Chen YY. Navigating CAR-T cells through the solid-tumour microenvironment. Nat Rev Drug Discovery. 2021;20(7):531\u201350.","journal-title":"Nat Rev Drug Discovery"},{"issue":"51","key":"2923_CR108","volume":"1","author":"M Dal Bo","year":"2020","unstructured":"Dal Bo M, De Mattia E, Baboci L, Mezzalira S, Cecchin E, Assaraf YG, Toffoli G. New insights into the pharmacological, immunological, and CAR-T-cell approaches in the treatment of hepatocellular carcinoma. Drug Resist Updates. 2020;1(51): 100702.","journal-title":"Drug Resist Updates"},{"issue":"3","key":"2923_CR109","doi-asserted-by":"publisher","first-page":"41","DOI":"10.3390\/antib8030041","volume":"8","author":"WR Strohl","year":"2019","unstructured":"Strohl WR, Naso M. Bispecific T-cell redirection versus chimeric antigen receptor (CAR)-T cells as approaches to kill cancer cells. Antibodies. 2019;8(3):41.","journal-title":"Antibodies"},{"issue":"7","key":"2923_CR110","doi-asserted-by":"publisher","first-page":"e002723","DOI":"10.1136\/jitc-2021-002723","volume":"9","author":"K Kirtane","year":"2021","unstructured":"Kirtane K, Elmariah H, Chung CH, Abate-Daga D. Adoptive cellular therapy in solid tumor malignancies: review of the literature and challenges ahead. J Immunotherapy Cancer. 2021;9(7):e002723.","journal-title":"J Immunotherapy Cancer."},{"issue":"10297","key":"2923_CR111","doi-asserted-by":"publisher","first-page":"314","DOI":"10.1016\/S0140-6736(21)00933-8","volume":"398","author":"JG Berdeja","year":"2021","unstructured":"Berdeja JG, Madduri D, Usmani SZ, Jakubowiak A, Agha M, Cohen AD, Stewart AK, et al. Ciltacabtagene autoleucel, a B-cell maturation antigen-directed chimeric antigen receptor T-cell therapy in patients with relapsed or refractory multiple myeloma (CARTITUDE-1): a phase 1b\/2 open-label study. Lancet. 2021;398(10297):314\u201324. https:\/\/doi.org\/10.1016\/S0140-6736(21)00933-8. (Epub 2021 Jun 24. Erratum in: Lancet. 2021 Oct 2;398(10307):1216. PMID: 34175021).","journal-title":"Lancet"},{"issue":"10","key":"2923_CR112","doi-asserted-by":"publisher","first-page":"1779","DOI":"10.1080\/03007995.2021.1953456","volume":"37","author":"T Martin","year":"2021","unstructured":"Martin T, Usmani SZ, Schecter JM, Vogel M, Jackson CC, Deraedt W, et al. Matching-adjusted indirect comparison of efficacy outcomes for ciltacabtagene autoleucel in CARTITUDE-1 versus idecabtagene vicleucel in KarMMa for the treatment of patients with relapsed or refractory multiple myeloma. Curr Med Res Opin. 2021;37(10):1779\u201388. https:\/\/doi.org\/10.1080\/03007995.2021.1953456. (Curr Med Res Opin. 2021 Oct 6;:1-12. PMID: 34256668).","journal-title":"Curr Med Res Opin"},{"issue":"6","key":"2923_CR113","doi-asserted-by":"publisher","first-page":"1275","DOI":"10.1200\/JCO.22.00690","volume":"41","author":"JQ Mi","year":"2023","unstructured":"Mi JQ, Zhao W, Jing H, Fu W, Hu J, Chen L, et al. Phase II, open-label study of Ciltacabtagene Autoleucel, an Anti-B-Cell maturation antigen chimeric antigen receptor-T-Cell Therapy, in chinese patients with relapsed\/refractory multiple myeloma (CARTIFAN-1). J Clin Oncol. 2023;41(6):1275\u201384. https:\/\/doi.org\/10.1200\/JCO.22.00690. (Epub 2022 Oct 21 PMID: 36269898).","journal-title":"J Clin Oncol"},{"issue":"12","key":"2923_CR114","doi-asserted-by":"publisher","first-page":"e897","DOI":"10.1016\/S2352-3026(22)00284-8","volume":"9","author":"T Martin","year":"2022","unstructured":"Martin T, Lin Y, Agha M, Cohen AD, Htut M, Stewart AK, et al. Health-related quality of life in patients given ciltacabtagene autoleucel for relapsed or refractory multiple myeloma (CARTITUDE-1): a phase 1b\u20132, open-label study. Lancet Haematol. 2022;9(12):e897\u2013905. https:\/\/doi.org\/10.1016\/S2352-3026(22)00284-8. (Epub 2022 Oct 7 PMID: 36215989).","journal-title":"Lancet Haematol"},{"issue":"4","key":"2923_CR115","doi-asserted-by":"publisher","first-page":"335","DOI":"10.1056\/NEJMoa2303379","volume":"389","author":"J San-Miguel","year":"2023","unstructured":"San-Miguel J, Dhakal B, Yong K, Spencer A, Anguille S, Mateos MV, et al. Cilta-cel or standard care in lenalidomide-refractory multiple myeloma. N Engl J Med. 2023;389(4):335\u201347. https:\/\/doi.org\/10.1056\/NEJMoa2303379. (Epub 2023 Jun 5 PMID: 37272512).","journal-title":"N Engl J Med"},{"issue":"1","key":"2923_CR116","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1007\/s40261-021-01100-y","volume":"42","author":"K Weisel","year":"2022","unstructured":"Weisel K, Martin T, Krishnan A, Jagannath S, Londhe A, Nair S, et al. Comparative efficacy of ciltacabtagene autoleucel in CARTITUDE-1 vs physician\u2019s choice of therapy in the long-term follow-up of POLLUX, CASTOR, and EQUULEUS clinical trials for the treatment of patients with relapsed or refractory multiple myeloma. Clin Drug Investig. 2022;42(1):29\u201341. https:\/\/doi.org\/10.1007\/s40261-021-01100-y. (Epub 2021 Nov 25. PMID: 34822128; PMCID: PMC8755696).","journal-title":"Clin Drug Investig"},{"issue":"9","key":"2923_CR117","doi-asserted-by":"publisher","first-page":"690","DOI":"10.1016\/j.clml.2022.04.025","volume":"22","author":"K Weisel","year":"2022","unstructured":"Weisel K, Krishnan A, Schecter JM, Vogel M, Jackson CC, Deraedt W, et al. Matching-adjusted indirect treatment comparison to assess the comparative efficacy of Ciltacabtagene Autoleucel in CARTITUDE-1 versus belantamab mafodotin in DREAMM-2, Selinexor-Dexamethasone in STORM Part 2, and melphalan flufenamide-dexamethasone in HORIZON for the treatment of patients with triple-class exposed relapsed or refractory multiple myeloma. Clin Lymphoma Myeloma Leuk. 2022;22(9):690\u2013701. https:\/\/doi.org\/10.1016\/j.clml.2022.04.025. (Epub 2022 May 23 PMID: 35764490).","journal-title":"Clin Lymphoma Myeloma Leuk"},{"issue":"8","key":"2923_CR118","doi-asserted-by":"publisher","first-page":"705","DOI":"10.1056\/NEJMoa2024850","volume":"384","author":"NC Munshi","year":"2021","unstructured":"Munshi NC, Anderson LD Jr, Shah N, Madduri D, Berdeja J, Lonial S, et al. Idecabtagene vicleucel in relapsed and refractory multiple myeloma. N Engl J Med. 2021;384(8):705\u201316. https:\/\/doi.org\/10.1056\/NEJMoa2024850. (PMID: 33626253).","journal-title":"N Engl J Med"},{"issue":"6","key":"2923_CR119","doi-asserted-by":"publisher","first-page":"116","DOI":"10.1038\/s41408-021-00507-2","volume":"11","author":"S Jagannath","year":"2021","unstructured":"Jagannath S, Lin Y, Goldschmidt H, Reece D, Nooka A, Senin A, et al. Comparison of idecabtagene vicleucel with real-world outcomes in relapsed and refractory multiple myeloma. Blood Cancer J. 2021;11(6):116. https:\/\/doi.org\/10.1038\/s41408-021-00507-2. (PMID:34145225;PMCID:PMC8213772).","journal-title":"Blood Cancer J"},{"issue":"11","key":"2923_CR120","doi-asserted-by":"publisher","first-page":"1002","DOI":"10.1056\/NEJMoa2213614","volume":"388","author":"P Rodriguez-Otero","year":"2023","unstructured":"Rodriguez-Otero P, Ailawadhi S, Arnulf B, Patel K, Cavo M, Nooka AK, et al. Ide-cel or standard regimens in relapsed and refractory multiple myeloma. N Engl J Med. 2023;388(11):1002\u201314. https:\/\/doi.org\/10.1056\/NEJMoa2213614. (Epub 2023 Feb 10 PMID: 36762851).","journal-title":"N Engl J Med"},{"issue":"9","key":"2923_CR121","doi-asserted-by":"publisher","first-page":"2286","DOI":"10.1038\/s41591-023-02496-0","volume":"29","author":"Y Lin","year":"2023","unstructured":"Lin Y, Raje NS, Berdeja JG, Siegel DS, Jagannath S, Madduri D, et al. Idecabtagene vicleucel for relapsed and refractory multiple myeloma: post hoc 18-month follow-up of a phase 1 trial. Nat Med. 2023;29(9):2286\u201394. https:\/\/doi.org\/10.1038\/s41591-023-02496-0.","journal-title":"Nat Med"},{"key":"2923_CR122","doi-asserted-by":"publisher","DOI":"10.1016\/j.leukres.2023.107074","volume":"129","author":"M Delforge","year":"2023","unstructured":"Delforge M, Otero PR, Shah N, Moshkovich O, Braverman J, Dhanda DS, et al. Analysis of patient-reported experiences up to 2 years after receiving idecabtagene vicleucel (ide-cel, bb2121) for relapsed or refractory multiple myeloma: Longitudinal findings from the phase 2 KarMMa trial. Leuk Res. 2023;129: 107074. https:\/\/doi.org\/10.1016\/j.leukres.2023.107074. (Epub 2023 Apr 3 PMID: 37087950).","journal-title":"Leuk Res"},{"issue":"10","key":"2923_CR123","doi-asserted-by":"publisher","first-page":"4626","DOI":"10.1007\/s12325-023-02623-w","volume":"40","author":"N McGarvey","year":"2023","unstructured":"McGarvey N, Ung B, Carattini T, Imanak K, Lee A, Campbell TB, et al. Postinfusion costs associated with idecabtagene vicleucel treatment for patients with relapsed\/refractory multiple myeloma in the KarMMa Trial. Adv Ther. 2023;40(10):4626\u201338. https:\/\/doi.org\/10.1007\/s12325-023-02623-w. (Epub 2023 Aug 19. PMID: 37597153; PMCID: PMC10499666).","journal-title":"Adv Ther"},{"issue":"3","key":"2923_CR124","doi-asserted-by":"publisher","first-page":"e216","DOI":"10.1016\/S2352-3026(24)00005-X","volume":"11","author":"M Delforge","year":"2024","unstructured":"Delforge M, Patel K, Eliason L, Dhanda D, Shi L, Guo S, et al. Health-related quality of life in patients with triple-class exposed relapsed and refractory multiple myeloma treated with idecabtagene vicleucel or standard regimens: patient-reported outcomes from the phase 3, randomized, open-label KarMMa-3 clinical trial. Lancet Haematol. 2024;11(3):e216\u201327. https:\/\/doi.org\/10.1016\/S2352-3026(24)00005-X. (Erratum.In:LancetHaematol.2024Mar12; PMID:38423700).","journal-title":"Lancet Haematol"},{"issue":"26","key":"2923_CR125","doi-asserted-by":"publisher","first-page":"2531","DOI":"10.1056\/NEJMoa1707447","volume":"377","author":"SS Neelapu","year":"2017","unstructured":"Neelapu SS, Locke FL, Bartlett NL, Lekakis LJ, Miklos DB, Jacobson CA, et al. Axicabtagene Ciloleucel CAR T-Cell therapy in refractory large B-Cell lymphoma. N Engl J Med. 2017;377(26):2531\u201344. https:\/\/doi.org\/10.1056\/NEJMoa1707447. (Epub 2017 Dec 10. PMID: 29226797; PMCID: PMC5882485).","journal-title":"N Engl J Med"},{"issue":"1","key":"2923_CR126","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1016\/S1470-2045(21)00591-X","volume":"23","author":"CA Jacobson","year":"2022","unstructured":"Jacobson CA, Chavez JC, Sehgal AR, William BM, Munoz J, Salles G, et al. Axicabtagene ciloleucel in relapsed or refractory indolent non-Hodgkin lymphoma (ZUMA-5): a single-arm, multicentre, phase 2 trial. Lancet Oncol. 2022;23(1):91\u2013103. https:\/\/doi.org\/10.1016\/S1470-2045(21)00591-X. (Epub 2021 Dec 8 PMID: 34895487).","journal-title":"Lancet Oncol"},{"issue":"2","key":"2923_CR127","doi-asserted-by":"publisher","first-page":"148","DOI":"10.1056\/NEJMoa2301665","volume":"389","author":"JR Westin","year":"2023","unstructured":"Westin JR, Oluwole OO, Kersten MJ, Miklos DB, Perales MA, Ghobadi A, ZUMA-7 Investigators; Kite Members, et al. Survival with Axicabtagene Ciloleucel in large B-Cell lymphoma. N Engl J Med. 2023;389(2):148\u201357. https:\/\/doi.org\/10.1056\/NEJMoa2301665.","journal-title":"N Engl J Med"},{"issue":"7","key":"2923_CR128","doi-asserted-by":"publisher","first-page":"640","DOI":"10.1056\/NEJMoa2116133","volume":"386","author":"FL Locke","year":"2022","unstructured":"Locke FL, Miklos DB, Jacobson CA, Perales MA, Kersten MJ, Oluwole OO, All ZUMA-7 Investigators and Contributing Kite Members, et al. Axicabtagene ciloleucel as second-line therapy for large B-Cell lymphoma. N Engl J Med. 2022;386(7):640\u201354. https:\/\/doi.org\/10.1056\/NEJMoa2116133.","journal-title":"N Engl J Med"},{"issue":"4","key":"2923_CR129","doi-asserted-by":"publisher","first-page":"735","DOI":"10.1038\/s41591-022-01731-46","volume":"28","author":"SS Neelapu","year":"2022","unstructured":"Neelapu SS, Dickinson M, Munoz J, Ulrickson ML, Thieblemont C, Oluwole OO, et al. Axicabtagene ciloleucel as first-line therapy in high-risk large B-cell lymphoma: the phase 2 ZUMA-12 trial. Nat Med. 2022;28(4):735\u201342. https:\/\/doi.org\/10.1038\/s41591-022-01731-46. (Epub 2022 Mar 21. PMID: 35314842; PMCID: PMC9018426).","journal-title":"Nat Med"},{"issue":"10","key":"2923_CR130","doi-asserted-by":"publisher","first-page":"2593","DOI":"10.1038\/s41591-023-02572-5","volume":"29","author":"R Houot","year":"2023","unstructured":"Houot R, Bachy E, Cartron G, Gros FX, Morschhauser F, Oberic L, et al. Axicabtagene ciloleucel as second-line therapy in large B-cell lymphoma ineligible for autologous stem cell transplantation: a phase 2 trial. Nat Med. 2023;29(10):2593\u2013601. https:\/\/doi.org\/10.1038\/s41591-023-02572-5. (Epub 2023 Sep 14. Erratum in: Nat Med. 2023 Oct 9;: PMID: 37710005; PMCID: PMC10579056).","journal-title":"Nat Med"},{"issue":"4","key":"2923_CR131","doi-asserted-by":"publisher","first-page":"690","DOI":"10.1111\/bjh.17527","volume":"194","author":"OO Oluwole","year":"2021","unstructured":"Oluwole OO, Bouabdallah K, Mu\u00f1oz J, De Guibert S, Vose JM, Bartlett NL, et al. Prophylactic corticosteroid use in patients receiving axicabtagene ciloleucel for large B-cell lymphoma. Br J Haematol. 2021;194(4):690\u2013700. https:\/\/doi.org\/10.1111\/bjh.17527.","journal-title":"Br J Haematol"},{"issue":"3","key":"2923_CR132","doi-asserted-by":"publisher","first-page":"388","DOI":"10.1111\/bjh.17673","volume":"195","author":"MS Topp","year":"2021","unstructured":"Topp MS, van Meerten T, Houot R, Minnema MC, Bouabdallah K, Lugtenburg PJ, et al. Earlier corticosteroid use for adverse event management in patients receiving axicabtagene ciloleucel for large B-cell lymphoma. Br J Haematol. 2021;195(3):388\u201398. https:\/\/doi.org\/10.1111\/bjh.17673. (Epub 2021 Sep 29. PMID: 34590303; PMCID: PMC9293158).","journal-title":"Br J Haematol"},{"issue":"21","key":"2923_CR133","doi-asserted-by":"publisher","first-page":"2248","DOI":"10.1182\/blood.2022015478","volume":"140","author":"M Elsawy","year":"2022","unstructured":"Elsawy M, Chavez JC, Avivi I, Larouche JF, Wannesson L, Cwynarski K, et al. Patient-reported outcomes in ZUMA-7, a phase 3 study of axicabtagene ciloleucel in second-line large B-cell lymphoma. Blood. 2022;140(21):2248\u201360. https:\/\/doi.org\/10.1182\/blood.2022015478. (PMID:35839452;PMCID:PMC10653042).","journal-title":"Blood"},{"issue":"10","key":"2923_CR134","doi-asserted-by":"publisher","first-page":"1894","DOI":"10.1158\/1078-0432.CCR-22-3136","volume":"29","author":"JR Westin","year":"2023","unstructured":"Westin JR, Locke FL, Dickinson M, Ghobadi A, Elsawy M, van Meerten T, et al. Safety and efficacy of axicabtagene ciloleucel versus standard of care in patients 65 years of age or older with relapsed\/refractory large B-Cell lymphoma. Clin Cancer Res. 2023;29(10):1894\u2013905. https:\/\/doi.org\/10.1158\/1078-0432.CCR-22-3136. (PMID:36999993;PMCID:PMC10183830).","journal-title":"Clin Cancer Res"},{"issue":"5","key":"2923_CR135","doi-asserted-by":"publisher","first-page":"335.e1","DOI":"10.1016\/j.jtct.2023.01.008","volume":"29","author":"MJ Kersten","year":"2023","unstructured":"Kersten MJ, Qiao Y, Shah R, Solem C, Snider JT, To C, et al. Quality-adjusted time without symptoms or toxicity: analysis of axicabtagene ciloleucel versus standard of care in patients with relapsed\/refractory large B-Cell lymphoma. Transplant Cell Ther. 2023;29(5):335.e1-335.e8. https:\/\/doi.org\/10.1016\/j.jtct.2023.01.008.","journal-title":"Transplant Cell Ther"},{"issue":"11","key":"2923_CR136","doi-asserted-by":"publisher","first-page":"1324","DOI":"10.1002\/ajh.25951","volume":"95","author":"P Sesques","year":"2020","unstructured":"Sesques P, Ferrant E, Safar V, Wallet F, Tordo J, Dhomps A, et al. Commercial anti-CD19 CAR T-cell therapy for patients with relapsed\/refractory aggressive B-cell lymphoma in a European center. Am J Hematol. 2020;95(11):1324\u201333. https:\/\/doi.org\/10.1002\/ajh.25951. (Epub 2020 Aug 25 PMID: 32744738).","journal-title":"Am J Hematol"},{"issue":"1","key":"2923_CR137","doi-asserted-by":"publisher","first-page":"140","DOI":"10.1186\/s13045-021-01144-9","volume":"14","author":"DG Maloney","year":"2021","unstructured":"Maloney DG, Kuruvilla J, Liu FF, Kostic A, Kim Y, Bonner A, et al. Matching-adjusted indirect treatment comparison of liso-cel versus axi-cel in relapsed or refractory large B-cell lymphoma. J Hematol Oncol. 2021;14(1):140. https:\/\/doi.org\/10.1186\/s13045-021-01144-9. (PMID:34493319;PMCID:PMC8425084).","journal-title":"J Hematol Oncol"},{"issue":"10299","key":"2923_CR138","doi-asserted-by":"publisher","first-page":"491","DOI":"10.1016\/S0140-6736(21)01222-8","volume":"398","author":"BD Shah","year":"2021","unstructured":"Shah BD, Ghobadi A, Oluwole OO, Logan AC, Boissel N, Cassaday RD, et al. KTE-X19 for relapsed or refractory adult B-cell acute lymphoblastic leukemia: phase 2 results of the single-arm, open-label, multicentre ZUMA-3 study. Lancet. 2021;398(10299):491\u2013502. https:\/\/doi.org\/10.1016\/S0140-6736(21)01222-8. (Epub 2021 Jun 4 PMID: 34097852).","journal-title":"Lancet"},{"issue":"1","key":"2923_CR139","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1182\/blood.2020009098","volume":"138","author":"BD Shah","year":"2021","unstructured":"Shah BD, Bishop MR, Oluwole OO, Logan AC, Baer MR, Donnellan WB, et al. KTE-X19 anti-CD19 CAR T-cell therapy in adult relapsed\/refractory acute lymphoblastic leukemia: ZUMA-3 phase 1 results. Blood. 2021;138(1):11\u201322. https:\/\/doi.org\/10.1182\/blood.2020009098. (PMID:33827116;PMCID:PMC9999039).","journal-title":"Blood"},{"issue":"2","key":"2923_CR140","doi-asserted-by":"publisher","first-page":"e38","DOI":"10.1111\/bjh.17197","volume":"192","author":"P Jain","year":"2021","unstructured":"Jain P, Nastoupil L, Westin J, Lee HJ, Navsaria L, Steiner RE, et al. Outcomes and management of patients with mantle cell lymphoma after progression on brexucabtagene autoleucel therapy. Br J Haematol. 2021;192(2):e38\u201342. https:\/\/doi.org\/10.1111\/bjh.17197. (Epub 2020 Nov 5 PMID: 33152104).","journal-title":"Br J Haematol"},{"issue":"10343","key":"2923_CR141","doi-asserted-by":"publisher","first-page":"2294","DOI":"10.1016\/S0140-6736(22)00662-6","volume":"399","author":"M Kamdar","year":"2022","unstructured":"Kamdar M, Solomon SR, Arnason J, Johnston PB, Glass B, Bachanova V, et al. Lisocabtagene maraleucel versus standard of care with salvage chemotherapy followed by autologous stem cell transplantation as second-line treatment in patients with relapsed or refractory large B-cell lymphoma (TRANSFORM): results from an interim analysis of an open-label, randomized, phase 3 trial. Lancet. 2022;399(10343):2294\u2013308. https:\/\/doi.org\/10.1016\/S0140-6736(22)00662-6. (Erratum.In:Lancet.2022Jul16;400(10347):160 PMID: 35717989).","journal-title":"Lancet"},{"issue":"10254","key":"2923_CR142","doi-asserted-by":"publisher","first-page":"839","DOI":"10.1016\/S0140-6736(20)31366-0","volume":"396","author":"JS Abramson","year":"2020","unstructured":"Abramson JS, Palomba ML, Gordon LI, Lunning MA, Wang M, Arnason J, et al. Lisocabtagene maraleucel for patients with relapsed or refractory large B-cell lymphomas (TRANSCEND NHL 001): a multicentre seamless design study. Lancet. 2020;396(10254):839\u201352. https:\/\/doi.org\/10.1016\/S0140-6736(20)31366-0. (Epub 2020 Sep 1 PMID: 32888407).","journal-title":"Lancet"},{"issue":"8","key":"2923_CR143","doi-asserted-by":"publisher","first-page":"1066","DOI":"10.1016\/S1470-2045(22)00339-4","volume":"23","author":"A Sehgal","year":"2022","unstructured":"Sehgal A, Hoda D, Riedell PA, Ghosh N, Hamadani M, Hildebrandt GC, et al. Lisocabtagene maraleucel as second-line therapy in adults with relapsed or refractory large B-cell lymphoma who were not intended for haematopoietic stem cell transplantation (PILOT): an open-label, phase 2 study. Lancet Oncol. 2022;23(8):1066\u201377. https:\/\/doi.org\/10.1016\/S1470-2045(22)00339-4. (Epub 2022 Jul 12 PMID: 35839786).","journal-title":"Lancet Oncol"},{"issue":"14","key":"2923_CR144","doi-asserted-by":"publisher","first-page":"1675","DOI":"10.1182\/blood.2022018730","volume":"141","author":"JS Abramson","year":"2023","unstructured":"Abramson JS, Solomon SR, Arnason J, Johnston PB, Glass B, Bachanova V, et al. Lisocabtagene maraleucel as second-line therapy for large B-cell lymphoma: primary analysis of the phase 3 TRANSFORM study. Blood. 2023;141(14):1675\u201384. https:\/\/doi.org\/10.1182\/blood.2022018730. (PMID:36542826;PMCID:PMC10646768).","journal-title":"Blood"},{"issue":"12","key":"2923_CR145","doi-asserted-by":"publisher","first-page":"1794","DOI":"10.1182\/blood.2021011895","volume":"139","author":"T Siddiqi","year":"2022","unstructured":"Siddiqi T, Soumerai JD, Dorritie KA, Stephens DM, Riedell PA, Arnason J, et al. Phase 1 TRANSCEND CLL 004 study of lisocabtagene maraleucel in patients with relapsed\/refractory CLL or SLL. Blood. 2022;139(12):1794\u2013806. https:\/\/doi.org\/10.1182\/blood.2021011895. (PMID:34699592;PMCID:PMC10652916).","journal-title":"Blood"},{"issue":"10402","key":"2923_CR146","doi-asserted-by":"publisher","first-page":"641","DOI":"10.1016\/S0140-6736(23)01052-8","volume":"402","author":"T Siddiqi","year":"2023","unstructured":"Siddiqi T, Maloney DG, Kenderian SS, Brander DM, Dorritie K, Soumerai J, et al. Lisocabtagene maraleucel in chronic lymphocytic leukemia and small lymphocytic lymphoma (TRANSCEND CLL 004): a multicentre, open-label, single-arm, phase 1\u20132 study. Lancet. 2023;402(10402):641\u201354. https:\/\/doi.org\/10.1016\/S0140-6736(23)01052-8. (Epub 2023 Jun 6 PMID: 37295445).","journal-title":"Lancet"},{"issue":"24","key":"2923_CR147","doi-asserted-by":"publisher","first-page":"4889","DOI":"10.1002\/cam4.4820","volume":"11","author":"S Makita","year":"2022","unstructured":"Makita S, Yamamoto G, Maruyama D, Asano-Mori Y, Kaji D, Ananthakrishnan R, et al. Phase 2 results of lisocabtagene maraleucel in Japanese patients with relapsed\/refractory aggressive B-cell non-Hodgkin lymphoma. Cancer Med. 2022;11(24):4889\u201399. https:\/\/doi.org\/10.1002\/cam4.4820. (Epub 2022 May 26. PMID: 35619325; PMCID: PMC9761090).","journal-title":"Cancer Med"},{"issue":"23","key":"2923_CR148","doi-asserted-by":"publisher","first-page":"5969","DOI":"10.1182\/bloodadvances.2022008106","volume":"6","author":"JS Abramson","year":"2022","unstructured":"Abramson JS, Johnston PB, Kamdar M, Ibrahimi S, Izutsu K, Arnason J, et al. Health-related quality of life with lisocabtagene maraleucel vs standard of care in relapsed or refractory LBCL. Blood Adv. 2022;6(23):5969\u201379. https:\/\/doi.org\/10.1182\/bloodadvances.2022008106. (PMID:36149968;PMCID:PMC9713278).","journal-title":"Blood Adv"},{"issue":"8","key":"2923_CR149","doi-asserted-by":"publisher","first-page":"2245","DOI":"10.1182\/bloodadvances.2020003503","volume":"5","author":"DL Patrick","year":"2021","unstructured":"Patrick DL, Powers A, Jun MP, Kim Y, Garcia J, Dehner C, Maloney DG. Effect of lisocabtagene maraleucel on HRQoL and symptom severity in relapsed\/refractory large B-cell lymphoma. Blood Adv. 2021;5(8):2245\u201355. https:\/\/doi.org\/10.1182\/bloodadvances.2020003503. (PMID:33904895;PMCID:PMC8095132).","journal-title":"Blood Adv"},{"issue":"3","key":"2923_CR150","doi-asserted-by":"publisher","first-page":"573","DOI":"10.1080\/10428194.2022.2160200","volume":"64","author":"H Van Le","year":"2023","unstructured":"Van Le H, Van Naarden BK, Nowakowski GS, Sermer D, Radford J, Townsend W, et al. Use of a real-world synthetic control arm for direct comparison of lisocabtagene maraleucel and conventional therapy in relapsed\/refractory large B-cell lymphoma. Leuk Lymphoma. 2023;64(3):573\u201385. https:\/\/doi.org\/10.1080\/10428194.2022.2160200. (Epub 2023 Feb 8 PMID: 36755418).","journal-title":"Leuk Lymphoma"},{"issue":"5","key":"2923_CR151","doi-asserted-by":"publisher","first-page":"439","DOI":"10.1056\/NEJMoa1709866","volume":"378","author":"SL Maude","year":"2018","unstructured":"Maude SL, Laetsch TW, Buechner J, Rives S, Boyer M, Bittencourt H, et al. Tisagenlecleucel in children and young adults with B-Cell lymphoblastic leukemia. N Engl J Med. 2018;378(5):439\u201348. https:\/\/doi.org\/10.1056\/NEJMoa1709866. (PMID:29385370;PMCID:PMC5996391).","journal-title":"N Engl J Med"},{"issue":"1","key":"2923_CR152","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1056\/NEJMoa1804980","volume":"380","author":"SJ Schuster","year":"2019","unstructured":"Schuster SJ, Bishop MR, Tam CS, Waller EK, Borchmann P, McGuirk JP, et al. Tisagenlecleucel in adult relapsed or refractory diffuse large B-Cell lymphoma. N Engl J Med. 2019;380(1):45\u201356. https:\/\/doi.org\/10.1056\/NEJMoa1804980. (Epub 2018 Dec 1 PMID: 30501490).","journal-title":"N Engl J Med"},{"issue":"2","key":"2923_CR153","doi-asserted-by":"publisher","first-page":"325","DOI":"10.1038\/s41591-021-01622-0","volume":"28","author":"NH Fowler","year":"2022","unstructured":"Fowler NH, Dickinson M, Dreyling M, Martinez-Lopez J, Kolstad A, Butler J, et al. Tisagenlecleucel in adult relapsed or refractory follicular lymphoma: the phase 2 ELARA trial. Nat Med. 2022;28(2):325\u201332. https:\/\/doi.org\/10.1038\/s41591-021-01622-0. (Epub 2021 Dec 17 PMID: 34921238).","journal-title":"Nat Med"},{"issue":"7","key":"2923_CR154","doi-asserted-by":"publisher","first-page":"629","DOI":"10.1056\/NEJMoa2116596","volume":"386","author":"MR Bishop","year":"2022","unstructured":"Bishop MR, Dickinson M, Purtill D, Barba P, Santoro A, Hamad N, et al. Second-line tisagenlecleucel or standard care in aggressive B-Cell lymphoma. N Engl J Med. 2022;386(7):629\u201339. https:\/\/doi.org\/10.1056\/NEJMoa2116596. (Epub 2021 Dec 14 PMID: 34904798).","journal-title":"N Engl J Med"},{"issue":"10","key":"2923_CR155","doi-asserted-by":"publisher","first-page":"1403","DOI":"10.1016\/S1470-2045(21)00375-2","volume":"22","author":"SJ Schuster","year":"2021","unstructured":"Schuster SJ, Tam CS, Borchmann P, Worel N, McGuirk JP, Holte H. Long-term clinical outcomes of tisagenlecleucel in patients with relapsed or refractory aggressive B-cell lymphomas (JULIET): a multicentre, open-label, single-arm, phase 2 study. Lancet Oncol. 2021;22(10):1403\u201315. https:\/\/doi.org\/10.1016\/S1470-2045(21)00375-2. (Epub 2021 Sep 10 PMID: 34516954).","journal-title":"Lancet Oncol"},{"issue":"9","key":"2923_CR156","doi-asserted-by":"publisher","first-page":"1664","DOI":"10.1200\/JCO.22.00642","volume":"41","author":"TW Laetsch","year":"2023","unstructured":"Laetsch TW, Maude SL, Rives S, Hiramatsu H, Bittencourt H, Bader P, et al. Three-year update of tisagenlecleucel in pediatric and young adult patients with relapsed\/refractory acute lymphoblastic leukemia in the ELIANA Trial. J Clin Oncol. 2023;41(9):1664\u20139. https:\/\/doi.org\/10.1200\/JCO.22.00642. (Epub 2022 Nov 18. PMID: 36399695; PMCID: PMC10022844).","journal-title":"J Clin Oncol"},{"issue":"3","key":"2923_CR157","doi-asserted-by":"publisher","first-page":"560","DOI":"10.1182\/bloodadvances.2019000525","volume":"4","author":"R Awasthi","year":"2020","unstructured":"Awasthi R, Pacaud L, Waldron E, Tam CS, J\u00e4ger U, Borchmann P, et al. Tisagenlecleucel cellular kinetics, dose, and immunogenicity in relation to clinical factors in relapsed\/refractory DLBCL. Blood Adv. 2020;4(3):560\u201372. https:\/\/doi.org\/10.1182\/bloodadvances.2019000525. (PMID:32045475;PMCID:PMC7013261).","journal-title":"Blood Adv"},{"issue":"15","key":"2923_CR158","doi-asserted-by":"publisher","first-page":"2306","DOI":"10.1182\/blood.2021014738","volume":"139","author":"MJ Frigault","year":"2022","unstructured":"Frigault MJ, Dietrich J, Gallagher K, Roschewski M, Jordan JT, Forst D, et al. Safety and efficacy of tisagenlecleucel in primary CNS lymphoma: a phase 1\/2 clinical trial. Blood. 2022;139(15):2306\u201315. https:\/\/doi.org\/10.1182\/blood.2021014738. (PMID:35167655;PMCID:PMC9012129).","journal-title":"Blood"},{"issue":"22","key":"2923_CR159","doi-asserted-by":"publisher","first-page":"5835","DOI":"10.1182\/bloodadvances.2022008150","volume":"6","author":"G Salles","year":"2022","unstructured":"Salles G, Schuster SJ, Dreyling M, Fischer L, Kuruvilla J, Patten PEM, et al. Efficacy comparison of tisagenlecleucel vs usual care in patients with relapsed or refractory follicular lymphoma. Blood Adv. 2022;6(22):5835\u201343. https:\/\/doi.org\/10.1182\/bloodadvances.2022008150. (PMID:35973192;PMCID:PMC9649992).","journal-title":"Blood Adv"},{"issue":"23","key":"2923_CR160","doi-asserted-by":"publisher","first-page":"4980","DOI":"10.1182\/bloodadvances.2020003844","volume":"5","author":"K Thudium Mueller","year":"2021","unstructured":"Thudium Mueller K, Grupp SA, Maude SL, Levine JE, Pulsipher MA, Boyer MW, et al. Tisagenlecleucel immunogenicity in relapsed\/refractory acute lymphoblastic leukemia and diffuse large B-cell lymphoma. Blood Adv. 2021;5(23):4980\u201391. https:\/\/doi.org\/10.1182\/bloodadvances.2020003844. (PMID:34432863;PMCID:PMC9153050).","journal-title":"Blood Adv"},{"issue":"11","key":"2923_CR161","doi-asserted-by":"publisher","first-page":"2283","DOI":"10.1182\/bloodadvances.2022007779","volume":"7","author":"U Jaeger","year":"2023","unstructured":"Jaeger U, Worel N, McGuirk JP, Riedell PA, Fleury I, Du Y, et al. Safety and efficacy of tisagenlecleucel plus pembrolizumab in patients with r\/r DLBCL: phase 1b PORTIA study results. Blood Adv. 2023;7(11):2283\u20136. https:\/\/doi.org\/10.1182\/bloodadvances.2022007779. (PMID:36044388;PMCID:PMC10225880).","journal-title":"Blood Adv"},{"key":"2923_CR162","doi-asserted-by":"publisher","first-page":"720","DOI":"10.1073\/pnas.90.2.720","volume":"90","author":"Z Eshhar","year":"1993","unstructured":"Eshhar Z, Waks T, Gross G, Schindler DG. Specific activation and targeting of cytotoxic lymphocytes through chimeric single chains consisting of antibody-binding domains and the gamma or zeta subunits of the immunoglobulin and T-cell receptors. Proc Natl Acad Sci U S A. 1993;90:720\u20134.","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"1","key":"2923_CR163","doi-asserted-by":"publisher","first-page":"64","DOI":"10.1186\/s12935-023-02902-0","volume":"23","author":"HE Marei","year":"2023","unstructured":"Marei HE, Hasan A, Pozzoli G, Cenciarelli C. Cancer immunotherapy with immune checkpoint inhibitors (ICIs): potential, mechanisms of resistance, and strategies for reinvigorating T-cell responsiveness when resistance is acquired. Cancer Cell Int. 2023;23(1):64.","journal-title":"Cancer Cell Int"},{"issue":"2","key":"2923_CR164","doi-asserted-by":"publisher","first-page":"185","DOI":"10.1158\/2159-8290.CD-19-0790","volume":"10","author":"AJ Anandappa","year":"2020","unstructured":"Anandappa AJ, Wu CJ, Ott PA. Directing traffic: how to effectively drive T cells into tumors. Cancer Discov. 2020;10(2):185\u201397.","journal-title":"Cancer Discov"},{"key":"2923_CR165","doi-asserted-by":"publisher","first-page":"177ra38","DOI":"10.1126\/scitranslmed.3005930","volume":"5","author":"RJ Brentjens","year":"2013","unstructured":"Brentjens RJ, Davila ML, Riviere I, et al. CD19-targeted T cells rapidly induce molecular remissions in adults with chemotherapy-refractory acute lymphoblastic leukemia. Sci Transl Med. 2013;5:177ra38.","journal-title":"Sci Transl Med"},{"key":"2923_CR166","doi-asserted-by":"publisher","first-page":"958","DOI":"10.1158\/2159-8290.CD-17-1319","volume":"8","author":"BD Santomasso","year":"2018","unstructured":"Santomasso BD, Park JH, Salloum D, Riviere I, Flynn J, Mead E, Halton E, Wang X, Senechal B, Purdon T, et al. Clinical and biological correlates of neurotoxicity associated with CAR T-Cell therapy in patients with B-Cell acute lymphoblastic leukemia. Cancer Discov. 2018;8:958\u201371. https:\/\/doi.org\/10.1158\/2159-8290.CD-17-1319.","journal-title":"Cancer Discov"},{"issue":"10","key":"2923_CR167","doi-asserted-by":"publisher","first-page":"2764","DOI":"10.1158\/1078-0432.CCR-20-3863","volume":"27","author":"Y Hu","year":"2021","unstructured":"Hu Y, Zhou Y, Zhang M, Ge W, Li Y, Yang L, Wei G, Han L, Wang H, Yu S, Chen Y. CRISPR\/Cas9-engineered universal CD19\/CD22 dual-targeted CAR-T-cell therapy for relapsed\/refractory B-cell acute lymphoblastic leukemia. Clin Cancer Res. 2021;27(10):2764\u201372.","journal-title":"Clin Cancer Res"},{"key":"2923_CR168","doi-asserted-by":"publisher","first-page":"3885","DOI":"10.2147\/DDDT.S138765","volume":"12","author":"S Vairy","year":"2018","unstructured":"Vairy S, Garcia JL, Teira P, Bittencourt H. CTL019 (Tisagenlecleucel): CAR-T therapy for relapsed and refractory B-Cell acute lymphoblastic leukemia. Drug Des Dev Ther. 2018;12:3885\u201398. https:\/\/doi.org\/10.2147\/DDDT.S138765.","journal-title":"Drug Des Dev Ther"},{"key":"2923_CR169","doi-asserted-by":"publisher","first-page":"449","DOI":"10.1056\/NEJMoa1709919","volume":"378","author":"JH Park","year":"2018","unstructured":"Park JH, Rivi\u00e8re I, Wang X, et al. Long-term follow-up of CD19 CAR therapy in acute lymphoblastic leukemia. N Engl J Med. 2018;378:449\u201359.","journal-title":"N Engl J Med"},{"key":"2923_CR170","doi-asserted-by":"publisher","first-page":"396","DOI":"10.1007\/s11899-018-0470-x","volume":"13","author":"KC Pehlivan","year":"2018","unstructured":"Pehlivan KC, Duncan BB, Lee DW. CAR-T-cell therapy for acute lymphoblastic leukemia: transforming the treatment of relapsed and refractory disease. Curr Hematol Malig Rep. 2018;13:396\u2013406.","journal-title":"Curr Hematol Malig Rep"},{"key":"2923_CR171","doi-asserted-by":"publisher","first-page":"272","DOI":"10.1016\/j.omto.2020.06.016","volume":"18","author":"X Zhao","year":"2020","unstructured":"Zhao X, Yang J, Zhang X, Lu XA, Xiong M, Zhang J, Zhou X, Qi F, He T, Ding Y, et al. Efficacy and safety of CD28- or 4\u20131BB-based CD19 CAR-T Cells in B-Cell acute lymphoblastic leukemia. Mol Ther Oncolytics. 2020;18:272\u201381. https:\/\/doi.org\/10.1016\/j.omto.2020.06.016.","journal-title":"Mol Ther Oncolytics"},{"key":"2923_CR172","doi-asserted-by":"publisher","first-page":"517","DOI":"10.1016\/S0140-6736(14)61403-3","volume":"385","author":"DW Lee","year":"2015","unstructured":"Lee DW, Kochenderfer JN, Stetler-Stevenson M, et al. T cells expressing CD19 chimeric antigen receptors for acute lymphoblastic leukemia in children and young adults: a phase 1 dose-escalation trial. Lancet. 2015;385:517\u201328.","journal-title":"Lancet"},{"key":"2923_CR173","doi-asserted-by":"publisher","first-page":"177ra38","DOI":"10.1126\/scitranslmed.3005930","volume":"5","author":"RJ Brentjens","year":"2013","unstructured":"Brentjens RJ, Davila ML, Riviere I, Park J, Wang X, Cowell LG, Bartido S, Stefanski J, Taylor C, Olszewska M, et al. CD19-Targeted T cells rapidly induce molecular remissions in adults with chemotherapy-refractory acute lymphoblastic leukemia. Sci Transl Med. 2013;5:177ra38. https:\/\/doi.org\/10.1126\/scitranslmed.3005930.","journal-title":"Sci Transl Med"},{"key":"2923_CR174","doi-asserted-by":"publisher","first-page":"22425","DOI":"10.1126\/scitranslmed.3008226","volume":"6","author":"ML Davila","year":"2014","unstructured":"Davila ML, Riviere I, Wang X, et al. Efficacy and toxicity management of 19\u201328z CAR T-cell therapy in B-cell acute lymphoblastic leukemia. Sci Transl Med. 2014;6:22425.","journal-title":"Sci Transl Med"},{"key":"2923_CR175","doi-asserted-by":"publisher","first-page":"e321","DOI":"10.1634\/theoncologist.2019-0233","volume":"25","author":"S Ali","year":"2020","unstructured":"Ali S, Kjeken R, Niederlaender C, Markey G, Saunders TS, Opsata M, Moltu K, Bremnes B, Gr\u00f8nevik E, Muusse M, et al. The European medicines agency review of kymriah (Tisagenlecleucel) for the treatment of acute lymphoblastic leukemia and diffuse large B-Cell lymphoma. Oncologist. 2020;25:e321\u20137. https:\/\/doi.org\/10.1634\/theoncologist.2019-0233.","journal-title":"Oncologist"},{"issue":"37","key":"2923_CR176","doi-asserted-by":"publisher","DOI":"10.1016\/j.blre.2019.05.002","volume":"1","author":"P Hansrivijit","year":"2019","unstructured":"Hansrivijit P, Gale RP, Barrett J, Ciurea SO. Cellular therapy for acute myeloid leukemia\u2013current status and future prospects. Blood Rev. 2019;1(37): 100578.","journal-title":"Blood Rev"},{"issue":"10","key":"2923_CR177","doi-asserted-by":"publisher","first-page":"697","DOI":"10.3389\/fonc.2020.00697","volume":"6","author":"S Mardiana","year":"2020","unstructured":"Mardiana S, Gill S. CAR T cells for acute myeloid leukemia: state of the art and future directions. Front Oncol. 2020;6(10):697.","journal-title":"Front Oncol"},{"issue":"1","key":"2923_CR178","doi-asserted-by":"publisher","first-page":"272","DOI":"10.1016\/j.ymthe.2018.10.001","volume":"27","author":"D Gomes-Silva","year":"2019","unstructured":"Gomes-Silva D, Atilla E, Atilla PA, Mo F, Tashiro H, Srinivasan M, Lulla P, Rouce RH, Cabral JM, Ramos CA, Brenner MK. CD7 CAR T cells for the therapy of acute myeloid leukemia. Mol Ther. 2019;27(1):272\u201380.","journal-title":"Mol Ther"},{"issue":"3","key":"2923_CR179","doi-asserted-by":"publisher","first-page":"281","DOI":"10.1007\/s40259-021-00477-8","volume":"35","author":"S Fiorenza","year":"2021","unstructured":"Fiorenza S, Turtle CJ. CAR-T-cell therapy for acute myeloid leukemia: preclinical rationale, current clinical progress, and barriers to success. BioDrugs. 2021;35(3):281\u2013302.","journal-title":"BioDrugs"},{"issue":"2","key":"2923_CR180","doi-asserted-by":"publisher","first-page":"74","DOI":"10.1097\/MOH.0000000000000703","volume":"29","author":"J Koedam","year":"2022","unstructured":"Koedam J, Wermke M, Ehninger A, Cartellieri M, Ehninger G. Chimeric antigen receptor T-cell therapy in acute myeloid leukemia. Curr Opin Hematol. 2022;29(2):74\u201383.","journal-title":"Curr Opin Hematol"},{"issue":"2","key":"2923_CR181","doi-asserted-by":"publisher","first-page":"200","DOI":"10.3390\/jcm8020200","volume":"8","author":"S Hofmann","year":"2019","unstructured":"Hofmann S, Schubert ML, Wang L, He B, Neuber B, Dreger P, M\u00fcller-Tidow C, Schmitt M. Chimeric antigen receptor (CAR) T-cell therapy in acute myeloid leukemia (AML). J Clin Med. 2019;8(2):200.","journal-title":"J Clin Med"},{"issue":"7","key":"2923_CR182","doi-asserted-by":"publisher","first-page":"1302","DOI":"10.3324\/haematol.2018.208751","volume":"104","author":"KD Cummins","year":"2019","unstructured":"Cummins KD, Gill S. Chimeric antigen receptor T-cell therapy for acute myeloid leukemia: how close to reality? Haematologica. 2019;104(7):1302.","journal-title":"Haematologica"},{"issue":"1","key":"2923_CR183","doi-asserted-by":"publisher","first-page":"6436","DOI":"10.1038\/s41467-021-26683-0","volume":"12","author":"N El Khawanky","year":"2021","unstructured":"El Khawanky N, Hughes A, Yu W, Myburgh R, Matschulla T, Taromi S, Aumann K, Clarson J, Vinnakota JM, Shoumariyeh K, Miething C. Demethylating therapy increases anti-CD123 CAR T-cell cytotoxicity against acute myeloid leukemia. Nat Commun. 2021;12(1):6436.","journal-title":"Nat Commun"},{"issue":"2","key":"2923_CR184","doi-asserted-by":"publisher","first-page":"211","DOI":"10.1080\/13543784.2022.2032642","volume":"31","author":"T Badar","year":"2022","unstructured":"Badar T, Manna A, Gadd ME, Kharfan-Dabaja MA, Qin H. Prospect of CAR T-cell therapy in acute myeloid leukemia. Expert Opin Investig Drugs. 2022;31(2):211\u201320.","journal-title":"Expert Opin Investig Drugs"},{"issue":"11","key":"2923_CR185","doi-asserted-by":"publisher","first-page":"2122","DOI":"10.1038\/mt.2013.154","volume":"21","author":"DS Ritchie","year":"2013","unstructured":"Ritchie DS, Neeson PJ, Khot A, Peinert S, Tai T, Tainton K, Chen K, Shin M, Wall DM, H\u00f6nemann D, Gambell P. Persistence and efficacy of second generation CAR T-cell against the LeY antigen in acute myeloid leukemia. Mol Ther. 2013;21(11):2122\u20139.","journal-title":"Mol Ther"},{"issue":"3","key":"2923_CR186","doi-asserted-by":"publisher","first-page":"497","DOI":"10.3390\/cancers14030497","volume":"14","author":"J Marvin-Peek","year":"2022","unstructured":"Marvin-Peek J, Savani BN, Olalekan OO, Dholaria B. Challenges and advances in chimeric antigen receptor therapy for acute myeloid leukemia. Cancers. 2022;14(3):497.","journal-title":"Cancers"},{"issue":"10","key":"2923_CR187","doi-asserted-by":"publisher","first-page":"685","DOI":"10.3389\/fonc.2020.00685","volume":"27","author":"H Zhang","year":"2020","unstructured":"Zhang H, Gan WT, Hao WG, Wang PF, Li ZY, Chang LJ. Successful anti-CLL1 CAR T-cell therapy in secondary acute myeloid leukemia. Front Oncol. 2020;27(10):685.","journal-title":"Front Oncol"},{"issue":"11","key":"2923_CR188","doi-asserted-by":"publisher","first-page":"2944","DOI":"10.3390\/cancers15112944","volume":"15","author":"J Zarychta","year":"2023","unstructured":"Zarychta J, Kowalczyk A, Krawczyk M, Lejman M, Zawitkowska J. CAR-T cells immunotherapies for the treatment of acute myeloid leukemia\u2014recent advances. Cancers. 2023;15(11):2944.","journal-title":"Cancers"},{"issue":"24","key":"2923_CR189","doi-asserted-by":"publisher","first-page":"6157","DOI":"10.3390\/cancers13246157","volume":"13","author":"M Maucher","year":"2021","unstructured":"Maucher M, Srour M, Danhof S, Einsele H, Hudecek M, Yakoub-Agha I. Current limitations and perspectives of chimeric antigen receptor-T cells in acute myeloid leukemia. Cancers. 2021;13(24):6157.","journal-title":"Cancers"},{"issue":"3","key":"2923_CR190","doi-asserted-by":"publisher","first-page":"e191","DOI":"10.1016\/S2352-3026(22)00378-7","volume":"10","author":"DA Sallman","year":"2023","unstructured":"Sallman DA, Kerre T, Havelange V, Poir\u00e9 X, Lewalle P, Wang ES, Brayer JB, Davila ML, Moors I, Machiels JP, Awada A. CYAD-01, an autologous NKG2D-based CAR T-cell therapy, in relapsed or refractory acute myeloid leukemia and myelodysplastic syndromes or multiple myeloma (THINK): haematological cohorts of the dose escalation segment of a phase 1 trial. Lancet Haematol. 2023;10(3):e191-202.","journal-title":"Lancet Haematol"},{"key":"2923_CR191","doi-asserted-by":"publisher","first-page":"79","DOI":"10.1007\/978-3-030-94353-0_14","volume":"7","author":"O Tournilhac","year":"2022","unstructured":"Tournilhac O, Dreger P. Chronic lymphocytic leukemia. EBMT\/EHA CAR-T-Cell Handbook. 2022;7:79\u201382.","journal-title":"EBMT\/EHA CAR-T-Cell Handbook"},{"issue":"2","key":"2923_CR192","doi-asserted-by":"publisher","first-page":"220","DOI":"10.1111\/bjh.15918","volume":"186","author":"S Man","year":"2019","unstructured":"Man S, Henley P. Chronic lymphocytic leukemia: the role of T cells in a B-cell disease. Br J Haematol. 2019;186(2):220\u201333.","journal-title":"Br J Haematol"},{"issue":"5","key":"2923_CR193","doi-asserted-by":"publisher","first-page":"563","DOI":"10.1038\/s41591-018-0010-1","volume":"24","author":"JA Fraietta","year":"2018","unstructured":"Fraietta JA, Lacey SF, Orlando EJ, Pruteanu-Malinici I, Gohil M, Lundh S, Boesteanu AC, Wang Y, O\u2019Connor RS, Hwang WT, Pequignot E. Determinants of response and resistance to CD19 chimeric antigen receptor (CAR) T-cell therapy of chronic lymphocytic leukemia. Nat Med. 2018;24(5):563\u201371.","journal-title":"Nat Med"},{"issue":"11","key":"2923_CR194","doi-asserted-by":"publisher","first-page":"5536","DOI":"10.3390\/ijms22115536","volume":"22","author":"V Mancikova","year":"2021","unstructured":"Mancikova V, Smida M. Current state of CAR T-cell therapy in chronic lymphocytic leukemia. Int J Mol Sci. 2021;22(11):5536.","journal-title":"Int J Mol Sci"},{"key":"2923_CR195","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/s11864-016-0406-4","volume":"17","author":"N Singh","year":"2016","unstructured":"Singh N, Frey NV, Grupp SA, Maude SL. CAR T-cell therapy in acute lymphoblastic leukemia and potential for chronic lymphocytic leukemia. Curr Treat Options Oncol. 2016;17:1\u20131.","journal-title":"Curr Treat Options Oncol"},{"issue":"7","key":"2923_CR196","doi-asserted-by":"publisher","first-page":"1715","DOI":"10.3390\/cancers14071715","volume":"14","author":"BM Heyman","year":"2022","unstructured":"Heyman BM, Tzachanis D, Kipps TJ. Recent advances in CAR T-cell therapy for patients with chronic lymphocytic leukemia. Cancers. 2022;14(7):1715.","journal-title":"Cancers"},{"issue":"7","key":"2923_CR197","doi-asserted-by":"publisher","first-page":"1566","DOI":"10.1080\/10428194.2022.2043299","volume":"63","author":"S Tettamanti","year":"2022","unstructured":"Tettamanti S, Rotiroti MC, Giordano Attianese GM, Arcangeli S, Zhang R, Banerjee P, Galletti G, McManus S, Mazza M, Nicolini F, Martinelli G. Lenalidomide enhances CD23. CAR T-cell therapy in chronic lymphocytic leukemia. Leukemia Lymphoma. 2022;63(7):1566\u201379.","journal-title":"Leukemia Lymphoma"},{"issue":"4","key":"2923_CR198","doi-asserted-by":"publisher","first-page":"307","DOI":"10.1111\/sji.12331","volume":"82","author":"CL Lorentzen","year":"2015","unstructured":"Lorentzen CL, Straten PT. CD 19-Chimeric antigen receptor T cells for treatment of chronic lymphocytic leukemia and acute lymphoblastic leukemia. Scand J Immunol. 2015;82(4):307\u201319.","journal-title":"Scand J Immunol"},{"issue":"12","key":"2923_CR199","doi-asserted-by":"publisher","first-page":"852","DOI":"10.1016\/j.clml.2017.07.007","volume":"17","author":"AR Mato","year":"2017","unstructured":"Mato AR, Thompson MC, Nabhan C, Svoboda J, Schuster SJ. Chimeric antigen receptor T-cell therapy for chronic lymphocytic leukemia: a narrative review. Clin Lymphoma Myeloma Leuk. 2017;17(12):852\u20136.","journal-title":"Clin Lymphoma Myeloma Leuk"},{"issue":"5","key":"2923_CR200","doi-asserted-by":"publisher","first-page":"3647","DOI":"10.3390\/curroncol29050293","volume":"29","author":"Z Todorovic","year":"2022","unstructured":"Todorovic Z, Todorovic D, Markovic V, Ladjevac N, Zdravkovic N, Djurdjevic P, Arsenijevic N, Milovanovic M, Arsenijevic A, Milovanovic J. CAR T-cell therapy for chronic lymphocytic leukemia: successes and shortcomings. Curr Oncol. 2022;29(5):3647\u201357.","journal-title":"Curr Oncol"},{"issue":"2","key":"2923_CR201","doi-asserted-by":"publisher","first-page":"291","DOI":"10.1053\/j.seminoncol.2016.02.006","volume":"43","author":"JA Fraietta","year":"2016","unstructured":"Fraietta JA, Schwab RD, Maus MV. Improving therapy of chronic lymphocytic leukemia with chimeric antigen receptor T cells. Seminars Oncol. 2016;43(2):291\u20139.","journal-title":"Seminars Oncol"},{"key":"2923_CR202","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s13045-018-0676-3","volume":"11","author":"Y Zou","year":"2018","unstructured":"Zou Y, Xu W, Li J. Chimeric antigen receptor-modified T-cell therapy in chronic lymphocytic leukemia. J Hematol Oncol. 2018;11:1\u20132.","journal-title":"J Hematol Oncol"},{"key":"2923_CR203","doi-asserted-by":"publisher","first-page":"725","DOI":"10.1056\/NEJMoa1103849","volume":"365","author":"DL Porter","year":"2011","unstructured":"Porter DL, Levine BL, Kalos M, Bagg A, June CH. Chimeric antigen receptor-modified T Cells in chronic lymphoid leukemia. N Engl J Med. 2011;365:725\u201333. https:\/\/doi.org\/10.1056\/NEJMoa1103849.","journal-title":"N Engl J Med"},{"issue":"25","key":"2923_CR204","doi-asserted-by":"publisher","first-page":"2862","DOI":"10.1200\/JCO.19.03237","volume":"38","author":"NV Frey","year":"2020","unstructured":"Frey NV, Gill S, Hexner EO, Schuster S, Nasta S, Loren A, Svoboda J, Stadtmauer E, Landsburg DJ, Mato A, Levine BL. Long-term outcomes from a randomized dose optimization study of chimeric antigen receptor modified T cells in relapsed chronic lymphocytic leukemia. J Clin Oncol. 2020;38(25):2862.","journal-title":"J Clin Oncol"},{"key":"2923_CR205","first-page":"2012","volume":"1","author":"P Koehler","year":"2012","unstructured":"Koehler P, Schmidt P, Hombach AA, Hallek M, Abken H. T cells for the adoptive therapy of B-cell chronic lymphocytic leukemia. Adv Hematol. 2012;1:2012.","journal-title":"Adv Hematol"},{"issue":"11","key":"2923_CR206","first-page":"1032","volume":"325","author":"MC Jaklevic","year":"2021","unstructured":"Jaklevic MC. CAR-T therapy is approved for nonhodgkin lymphoma. JAMA. 2021;325(11):1032.","journal-title":"JAMA"},{"key":"2923_CR207","unstructured":"Harun Achmad M. A Deep Insight Into CAR-T Cell Therapy in Non-Hodgkin Lymphoma: Application, Opportunities, and Future Directions. https:\/\/www.frontiersin.org\/journals\/immunology. 2021"},{"issue":"12","key":"2923_CR208","doi-asserted-by":"publisher","first-page":"751","DOI":"10.1016\/j.clml.2019.09.598","volume":"19","author":"A Kallam","year":"2019","unstructured":"Kallam A, Vose JM. Recent advances in CAR-T-cell therapy for non-Hodgkin lymphoma. Clin Lymphoma Myeloma Leuk. 2019;19(12):751\u20137.","journal-title":"Clin Lymphoma Myeloma Leuk"},{"issue":"1","key":"2923_CR209","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1016\/j.tmrv.2019.08.003","volume":"34","author":"JS Abramson","year":"2020","unstructured":"Abramson JS. Anti-CD19 CAR T-cell therapy for B-cell non-Hodgkin lymphoma. Transfus Med Rev. 2020;34(1):29\u201333.","journal-title":"Transfus Med Rev"},{"issue":"10","key":"2923_CR210","doi-asserted-by":"publisher","first-page":"849","DOI":"10.3389\/fonc.2020.00849","volume":"27","author":"C Vitale","year":"2020","unstructured":"Vitale C, Strati P. CAR T-cell therapy for B-cell non-Hodgkin lymphoma and chronic lymphocytic leukemia: clinical trials and real-world experiences. Front Oncol. 2020;27(10):849.","journal-title":"Front Oncol"},{"issue":"3","key":"2923_CR211","doi-asserted-by":"publisher","DOI":"10.1002\/acg2.54","volume":"2","author":"L Hill","year":"2019","unstructured":"Hill L, Lulla P, Heslop HE. CAR-T-cell therapy for non-Hodgkin lymphomas: a new treatment paradigm. Adv Cell Gene Therapy. 2019;2(3): e54.","journal-title":"Adv Cell Gene Therapy"},{"issue":"2","key":"2923_CR212","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1016\/j.retram.2018.03.005","volume":"66","author":"A Ghobadi","year":"2018","unstructured":"Ghobadi A. Chimeric antigen receptor T-cell therapy for non-Hodgkin lymphoma. Curr Res Translat Med. 2018;66(2):43\u20139.","journal-title":"Curr Res Translat Med"},{"issue":"11","key":"2923_CR213","volume":"7","author":"Z Jackson","year":"2020","unstructured":"Jackson Z, Roe A, Sharma AA, Zamborsky K, Schauner R, Caimi PF, Krueger W, Worden A, Schneider D, Orentas R, Dropulic B. Automated manufacture of autologous CD19 CAR-T cells for treatment of nonhodgkin lymphoma. Front Immunol. 2020;7(11): 561200.","journal-title":"Front Immunol"},{"issue":"11","key":"2923_CR214","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2021.664688","volume":"28","author":"L Vercellino","year":"2021","unstructured":"Vercellino L, de Jong D, Di Blasi R, Kanoun S, Reshef R, Schwartz LH, Dercle L. Current and future role of medical imaging in guiding the management of patients with relapsed and refractory nonhodgkin lymphoma treated with CAR T-Cell therapy. Front Oncol. 2021;28(11): 664688.","journal-title":"Front Oncol"},{"issue":"1","key":"2923_CR215","doi-asserted-by":"publisher","first-page":"134","DOI":"10.1038\/s41392-020-00256-x","volume":"5","author":"J Wei","year":"2020","unstructured":"Wei J, Liu Y, Wang C, Zhang Y, Tong C, Dai G, Wang W, Rasko JE, Melenhorst JJ, Qian W, Liang A. The model of cytokine release syndrome in CAR T-cell treatment for B-cell non-Hodgkin lymphoma. Signal Transduct Target Ther. 2020;5(1):134.","journal-title":"Signal Transduct Target Ther"},{"issue":"20","key":"2923_CR216","doi-asserted-by":"publisher","first-page":"4291","DOI":"10.1182\/bloodadvances.2021005304","volume":"5","author":"C Ho","year":"2021","unstructured":"Ho C, Ruella M, Levine BL, Svoboda J. Adoptive T-cell therapy for Hodgkin lymphoma. Blood Adv. 2021;5(20):4291\u2013302.","journal-title":"Blood Adv"},{"issue":"2","key":"2923_CR217","doi-asserted-by":"publisher","DOI":"10.1097\/HS9.0000000000000185","volume":"3","author":"G Hopfinger","year":"2019","unstructured":"Hopfinger G, J\u00e4ger U, Worel N. CAR-T-cell therapy in diffuse large B-cell lymphoma: hype and hope. Hemasphere. 2019;3(2): e185.","journal-title":"Hemasphere"},{"issue":"67","key":"2923_CR218","doi-asserted-by":"publisher","first-page":"165","DOI":"10.1146\/annurev-med-051914-021702","volume":"14","author":"CA Ramos","year":"2016","unstructured":"Ramos CA, Heslop HE, Brenner MK. CAR-T-cell therapy for lymphoma. Annu Rev Med. 2016;14(67):165\u201383.","journal-title":"Annu Rev Med"},{"issue":"3","key":"2923_CR219","doi-asserted-by":"publisher","first-page":"S63","DOI":"10.1016\/j.bbmt.2018.12.145","volume":"25","author":"CA Ramos","year":"2019","unstructured":"Ramos CA, Bilgi M, Gerken C, Dakhova O, Mei Z, Wu MF, Grilley B, Gee AP, Rooney CM, Dotti G, Savoldo B. CD30-chimeric antigen receptor (CAR) T cells for therapy of Hodgkin lymphoma (HL). Biol Blood Marrow Transplant. 2019;25(3):S63.","journal-title":"Biol Blood Marrow Transplant"},{"issue":"5","key":"2923_CR220","doi-asserted-by":"publisher","first-page":"42","DOI":"10.1007\/s11864-021-00840-5","volume":"22","author":"X Andrade-Gonzalez","year":"2021","unstructured":"Andrade-Gonzalez X, Ansell SM. Novel therapies in the treatment of hodgkin lymphoma. Curr Treat Options Oncol. 2021;22(5):42.","journal-title":"Curr Treat Options Oncol"},{"issue":"1","key":"2923_CR221","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1038\/nrclinonc.2017.128","volume":"15","author":"JN Brudno","year":"2018","unstructured":"Brudno JN, Kochenderfer JN. Chimeric antigen receptor T-cell therapies for lymphoma. Nat Rev Clin Oncol. 2018;15(1):31\u201346.","journal-title":"Nat Rev Clin Oncol"},{"issue":"23","key":"2923_CR222","doi-asserted-by":"publisher","first-page":"185","DOI":"10.1182\/blood.V126.23.185.185","volume":"126","author":"CA Ramos","year":"2015","unstructured":"Ramos CA, Ballard B, Liu E, Dakhova O, Mei Z, Liu H, Grilley B, Rooney CM, Gee AP, Chang BH, Bollard CM. Chimeric T cells for therapy of CD30+ Hodgkin and non-Hodgkin lymphomas. Blood. 2015;126(23):185.","journal-title":"Blood"},{"issue":"2","key":"2923_CR223","doi-asserted-by":"publisher","first-page":"197","DOI":"10.3390\/jpm12020197","volume":"12","author":"JA Meier","year":"2022","unstructured":"Meier JA, Savoldo B, Grover NS. The emerging role of CAR T-cell therapy in relapsed\/refractory hodgkin lymphoma. J Personal Med. 2022;12(2):197.","journal-title":"J Personal Med"},{"issue":"134","key":"2923_CR224","doi-asserted-by":"publisher","first-page":"4075","DOI":"10.1182\/blood-2019-123765","volume":"13","author":"T Siddiqi","year":"2019","unstructured":"Siddiqi T, Wang X, Palmer J, Popplewell LL, Nikolaenko L, Herrera AF, Budde LE, Lim L, Vyas V, Brown CE, Forman SJ. CD19-targeting CAR-T-cell therapy in CNS lymphoma. Blood. 2019;13(134):4075.","journal-title":"Blood"},{"issue":"4","key":"2923_CR225","doi-asserted-by":"publisher","first-page":"1255","DOI":"10.1182\/bloodadvances.2021005385","volume":"6","author":"TJ Voorhees","year":"2022","unstructured":"Voorhees TJ, Zhao B, Oldan J, Hucks G, Khandani A, Dittus C, Smith J, Morrison JK, Cheng CJ, Ivanova A, Park S. Pretherapy metabolic tumor volume is associated with response to CD30 CAR T cells in Hodgkin lymphoma. Blood Adv. 2022;6(4):1255\u201363.","journal-title":"Blood Adv"},{"issue":"10","key":"2923_CR226","first-page":"1022","volume":"132","author":"J Svoboda","year":"2018","unstructured":"Svoboda J, Rheingold SR, Gill SI, Grupp SA, Lacey SF, Kulikovskaya I, Suhoski MM, Melenhorst JJ, Loudon B, Mato AR, Nasta SD. Nonviral RNA chimeric antigen receptor\u2013modified T cells in patients with Hodgkin lymphoma. Blood J Am Soci Hematol. 2018;132(10):1022\u20136.","journal-title":"Blood J Am Soci Hematol"},{"issue":"21","key":"2923_CR227","doi-asserted-by":"publisher","first-page":"806","DOI":"10.1182\/blood.V124.21.806.806","volume":"124","author":"M Ruella","year":"2014","unstructured":"Ruella M, Kenderian SS, Shestova O, Chen T, Scholler J, Wasik MA, June CH, Gill SI. Novel chimeric antigen receptor T cells for the treatment of Hodgkin lymphoma. Blood. 2014;124(21):806.","journal-title":"Blood"},{"key":"2923_CR228","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/s00005-020-00599-x","volume":"68","author":"K Skorka","year":"2020","unstructured":"Skorka K, Ostapinska K, Malesa A, Giannopoulos K. The application of CAR-T cells in haematological malignancies. Arch Immunol Ther Exp. 2020;68:1\u20139.","journal-title":"Arch Immunol Ther Exp"},{"key":"2923_CR229","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s13045-019-0746-1","volume":"12","author":"H Wang","year":"2019","unstructured":"Wang H, Kaur G, Sankin AI, Chen F, Guan F, Zang X. Immune checkpoint blockade and CAR-T-cell therapy in hematologic malignancies. J Hematol Oncol. 2019;12:1\u201320.","journal-title":"J Hematol Oncol"},{"issue":"13","key":"2923_CR230","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2022.927153","volume":"10","author":"X Zhang","year":"2022","unstructured":"Zhang X, Zhu L, Zhang H, Xiao Y. CAR-T-cell therapy in hematological malignancies: current opportunities and challenges. Front Immunol. 2022;10(13): 927153.","journal-title":"Front Immunol"},{"issue":"12","key":"2923_CR231","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2021.780442","volume":"25","author":"PH Mehta","year":"2021","unstructured":"Mehta PH, Fiorenza S, Koldej RM, Jaworowski A, Quinn KM. T-cell fitness and autologous CAR T-cell therapy in haematologic malignancy. Front Immunol. 2021;25(12): 780442.","journal-title":"Front Immunol"},{"issue":"2","key":"2923_CR232","doi-asserted-by":"publisher","first-page":"e104","DOI":"10.1016\/S1470-2045(19)30729-6","volume":"21","author":"M Elsallab","year":"2020","unstructured":"Elsallab M, Levine BL, Wayne AS, Abou-El-Enein M. CAR T-cell product performance in haematological malignancies before and after marketing authorization. Lancet Oncol. 2020;21(2):e104\u201316.","journal-title":"Lancet Oncol"},{"issue":"3","key":"2923_CR233","doi-asserted-by":"publisher","first-page":"79","DOI":"10.1016\/j.retram.2019.05.002","volume":"67","author":"PJ Hayden","year":"2019","unstructured":"Hayden PJ, Sirait T, Koster L, Snowden JA, Yakoub-Agha I. An international survey on the management of patients receiving CAR T-cell therapy for haematological malignancies on behalf of the Chronic Malignancies Working Party of EBMT. Curr Res Translat Med. 2019;67(3):79\u201388.","journal-title":"Curr Res Translat Med"},{"issue":"12","key":"2923_CR234","doi-asserted-by":"publisher","first-page":"1625","DOI":"10.1016\/S1470-2045(19)30641-2","volume":"20","author":"F Efficace","year":"2019","unstructured":"Efficace F, Vignetti M. Quality of life and CAR-T-cell therapy in children, adolescents, and young adults with haematological malignancies. Lancet Oncol. 2019;20(12):1625\u20136.","journal-title":"Lancet Oncol"},{"issue":"12","key":"2923_CR235","doi-asserted-by":"publisher","DOI":"10.1136\/bmjopen-2017-019321","volume":"7","author":"EJ Grigor","year":"2017","unstructured":"Grigor EJ, Fergusson DA, Haggar F, Kekre N, Atkins H, Shorr R, Holt RA, Hutton B, Ramsay T, Seftel M, Jonker D. Efficacy and safety of chimeric antigen receptor T-cell (CAR-T) therapy in patients with haematological and solid malignancies: protocol for a systematic review and meta-analysis. BMJ Open. 2017;7(12): e019321.","journal-title":"BMJ Open"},{"issue":"1","key":"2923_CR236","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1111\/bjh.13792","volume":"172","author":"S Maude","year":"2016","unstructured":"Maude S, Barrett DM. Current status of chimeric antigen receptor therapy for haematological malignancies. Br J Haematol. 2016;172(1):11\u201322.","journal-title":"Br J Haematol"},{"issue":"11","key":"2923_CR237","doi-asserted-by":"publisher","first-page":"1455","DOI":"10.1080\/14787210.2022.2128762","volume":"20","author":"G Telli Dizman","year":"2022","unstructured":"Telli Dizman G, Aguado JM, Fern\u00e1ndez-Ruiz M. Risk of infection in patients with hematological malignancies receiving CAR T-cell therapy: systematic review and meta-analysis. Expert Rev Anti Infect Ther. 2022;20(11):1455\u201376.","journal-title":"Expert Rev Anti Infect Ther"},{"issue":"1","key":"2923_CR238","doi-asserted-by":"publisher","first-page":"e6","DOI":"10.4110\/in.2022.22.e6","volume":"22","author":"C Hupperetz","year":"2022","unstructured":"Hupperetz C, Lah S, Kim H, Kim CH. CAR T-cell immunotherapy beyond haematological malignancy. Immune network. 2022;22(1):e6.","journal-title":"Immune network."},{"issue":"26","key":"2923_CR239","first-page":"3312","volume":"127","author":"JH Park","year":"2016","unstructured":"Park JH, Geyer MB, Brentjens RJ. CD19-targeted CAR T-cell therapeutics for hematologic malignancies: interpreting clinical outcomes to date. Blood J Am Soci Hematol. 2016;127(26):3312\u201320.","journal-title":"Blood J Am Soci Hematol"},{"issue":"2","key":"2923_CR240","doi-asserted-by":"publisher","first-page":"194","DOI":"10.3390\/pharmaceutics12020194","volume":"12","author":"G Roex","year":"2020","unstructured":"Roex G, Feys T, Beguin Y, Kerre T, Poir\u00e9 X, Lewalle P, Vandenberghe P, Bron D, Anguille S. Chimeric antigen receptor-T-cell therapy for B-cell hematological malignancies: an update of the pivotal clinical trial data. Pharmaceutics. 2020;12(2):194.","journal-title":"Pharmaceutics"},{"issue":"9","key":"2923_CR241","doi-asserted-by":"publisher","first-page":"2317","DOI":"10.1038\/s41375-020-0930-x","volume":"34","author":"N Gagelmann","year":"2020","unstructured":"Gagelmann N, Riecken K, Wolschke C, Berger C, Ayuk FA, Fehse B, Kr\u00f6ger N. Development of CAR-T-cell therapies for multiple myeloma. Leukemia. 2020;34(9):2317\u201332.","journal-title":"Leukemia"},{"issue":"6","key":"2923_CR242","doi-asserted-by":"publisher","first-page":"e446","DOI":"10.1016\/S2352-3026(21)00057-0","volume":"8","author":"NW Van de Donk","year":"2021","unstructured":"Van de Donk NW, Usmani SZ, Yong K. CAR T-cell therapy for multiple myeloma: state of the art and prospects. Lancet Haematol. 2021;8(6):e446\u201361.","journal-title":"Lancet Haematol"},{"issue":"14","key":"2923_CR243","doi-asserted-by":"publisher","first-page":"1101495","DOI":"10.3389\/fimmu.2023.1101495","volume":"20","author":"X Zhang","year":"2023","unstructured":"Zhang X, Zhang H, Lan H, Xiao Y. CAR-T-cell therapy in multiple myeloma: Current limitations and potential strategies. Front Immunol. 2023;20(14):1101495.","journal-title":"Front Immunol"},{"issue":"1","key":"2923_CR244","doi-asserted-by":"publisher","first-page":"868","DOI":"10.1038\/s41467-021-21177-5","volume":"12","author":"MK Samur","year":"2021","unstructured":"Samur MK, Fulciniti M, Aktas Samur A, Bazarbachi AH, Tai YT, Prabhala R, Alonso A, Sperling AS, Campbell T, Petrocca F, Hege K. Biallelic loss of BCMA as a resistance mechanism to CAR T-cell therapy in a patient with multiple myeloma. Nat Commun. 2021;12(1):868.","journal-title":"Nat Commun"},{"issue":"4","key":"2923_CR245","doi-asserted-by":"publisher","first-page":"84","DOI":"10.1038\/s41408-021-00469-5","volume":"11","author":"PJ Teoh","year":"2021","unstructured":"Teoh PJ, Chng WJ. CAR T-cell therapy in multiple myeloma: more room for improvement. Blood Cancer J. 2021;11(4):84.","journal-title":"Blood Cancer J"},{"key":"2923_CR246","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s13045-020-01001-1","volume":"13","author":"G Roex","year":"2020","unstructured":"Roex G, Timmers M, Wouters K, Campillo-Davo D, Flumens D, Schroyens W, Chu Y, Berneman ZN, Lion E, Luo F, Anguille S. Safety and clinical efficacy of BCMA CAR-T-cell therapy in multiple myeloma. J Hematol Oncol. 2020;13:1\u20134.","journal-title":"J Hematol Oncol"},{"key":"2923_CR247","first-page":"431","volume":"2023","author":"M Rameez","year":"2023","unstructured":"Rameez M, Khan AU, Ali RAZA. Breakthroughs in disease prevention and treatment. Curr Stud Health Life Sci. 2023;2023:431.","journal-title":"Curr Stud Health Life Sci"},{"issue":"54","key":"2923_CR248","doi-asserted-by":"publisher","DOI":"10.1016\/j.blre.2022.100929","volume":"1","author":"S Manier","year":"2022","unstructured":"Manier S, Ingegnere T, Escure G, Prodhomme C, Nudel M, Mitra S, Facon T. Current state and next-generation CAR-T cells in multiple myeloma. Blood Rev. 2022;1(54): 100929.","journal-title":"Blood Rev"},{"key":"2923_CR249","doi-asserted-by":"publisher","first-page":"12437","DOI":"10.3389\/fonc.2020.01243","volume":"10","author":"LG Rodr\u00edguez-Lobato","year":"2020","unstructured":"Rodr\u00edguez-Lobato LG, Ganzetti M, Fernandez de Larrea C, Hudecek M, Einsele H, Danhof S. CAR T cells in multiple myeloma: state of the art and future directions. Front Oncol. 2020;10:12437.","journal-title":"Front Oncol"},{"key":"2923_CR250","doi-asserted-by":"publisher","first-page":"1378944","DOI":"10.3389\/fimmu.2024.1378944","volume":"15","author":"L Levstek","year":"2024","unstructured":"Levstek L, Janzic L, Ihan A, Kopitar AN. Biomarkers for prediction of CAR T therapy outcomes: current and future perspectives. Front Immunol. 2024;15:1378944.","journal-title":"Front Immunol"},{"issue":"10","key":"2923_CR251","doi-asserted-by":"publisher","first-page":"2718","DOI":"10.3390\/cancers15102718","volume":"15","author":"DC Ziogas","year":"2023","unstructured":"Ziogas DC, Theocharopoulos C, Lialios PP, Foteinou D, Koumprentziotis IA, Xynos G, Gogas H. Beyond CTLA-4 and PD-1 inhibition: novel immune checkpoint molecules for melanoma treatment. Cancers. 2023;15(10):2718.","journal-title":"Cancers"},{"issue":"2","key":"2923_CR252","first-page":"86","volume":"2","author":"MM Ahmed","year":"2021","unstructured":"Ahmed MM. CAR-T-cell therapy: current advances and future research possibilities. J Sci Res Med Biol Sci. 2021;2(2):86\u2013116.","journal-title":"J Sci Res Med Biol Sci"},{"issue":"22","key":"2923_CR253","doi-asserted-by":"publisher","first-page":"8620","DOI":"10.3390\/ijms21228620","volume":"21","author":"AE Andrea","year":"2020","unstructured":"Andrea AE, Chiron A, Bessoles S, Hacein-Bey-Abina S. Engineering next-generation CAR-T cells for better toxicity management. Int J Mol Sci. 2020;21(22):8620.","journal-title":"Int J Mol Sci"},{"key":"2923_CR254","first-page":"1","volume":"1","author":"D Cohen","year":"2022","unstructured":"Cohen D, Luttwak E, Beyar-Katz O, Hazut Krauthammer S, Bar-On Y, Amit O, Gold R, Perry C, Avivi I, Ram R, Even-Sapir E. [18 F] FDG PET-CT in patients with DLBCL treated with CAR-T-cell therapy: a practical approach of reporting pre and post treatment studies. Eur J Nucl Med Mol Imaging. 2022;1:1.","journal-title":"Eur J Nucl Med Mol Imaging"},{"issue":"4","key":"2923_CR255","doi-asserted-by":"publisher","first-page":"904","DOI":"10.1038\/mt.2013.17","volume":"21","author":"CH Lamers","year":"2013","unstructured":"Lamers CH, Sleijfer S, Van Steenbergen S, Van Elzakker P, Van Krimpen B, Groot C, Vulto A, Den Bakker M, Oosterwijk E, Debets R, Gratama JW. Treatment of metastatic renal cell carcinoma with CAIX CAR-engineered T cells: clinical evaluation and management of on-target toxicity. Mol Ther. 2013;21(4):904\u201312.","journal-title":"Mol Ther"},{"issue":"11","key":"2923_CR256","volume":"9","author":"M Yang","year":"2020","unstructured":"Yang M, Wang L, Ni M, Sellner L, Kleist C, Schmitt M, Schmitt A. Presensitization of malignant B cells through venetoclax significantly improves the cytotoxic efficacy of CD19. CAR-T cells Front Immunol. 2020;9(11): 608167.","journal-title":"CAR-T cells Front Immunol"},{"issue":"3","key":"2923_CR257","doi-asserted-by":"publisher","first-page":"567","DOI":"10.1016\/j.ymthe.2024.02.016","volume":"32","author":"N Singh","year":"2024","unstructured":"Singh N. Analysis of pre-treatment tumors reveals gatekeepers of response to CAR T cells. Mol Therapy. 2024;32(3):567\u20138.","journal-title":"Mol Therapy"},{"issue":"9","key":"2923_CR258","doi-asserted-by":"publisher","first-page":"1872","DOI":"10.1038\/s41591-022-01916-x","volume":"28","author":"N Scholler","year":"2022","unstructured":"Scholler N, Perbost R, Locke FL, Jain MD, Turcan S, Danan C, Chang EC, Neelapu SS, Miklos DB, Jacobson CA, Lekakis LJ. Tumor immune contexture is a determinant of anti-CD19 CAR T-cell efficacy in large B-cell lymphoma. Nat Med. 2022;28(9):1872\u201382.","journal-title":"Nat Med"},{"issue":"142","key":"2923_CR259","doi-asserted-by":"publisher","first-page":"3519","DOI":"10.1182\/blood-2023-180115","volume":"28","author":"I Sdayoor","year":"2023","unstructured":"Sdayoor I, Shouval R, Fried S, Marcus R, Danylesko I, Yerushalmi R, Shem-Tov N, Itzhaki O, Jacoby E, Kedmi M, Nagler A. Pre-treatment pulmonary assessment have limited utility in B-Cell lymphoma patients treated with autologous Anti-CD19 CAR T-Cell therapy. Blood. 2023;28(142):3519.","journal-title":"Blood"},{"key":"2923_CR260","doi-asserted-by":"publisher","first-page":"1433","DOI":"10.1007\/s00262-016-1895-5","volume":"65","author":"A Holzinger","year":"2016","unstructured":"Holzinger A, Barden M, Abken H. The growing world of CAR T-cell trials: a systematic review. Cancer Immunol Immunother. 2016;65:1433\u201350.","journal-title":"Cancer Immunol Immunother"},{"issue":"2","key":"2923_CR261","first-page":"29","volume":"21","author":"LT Smith","year":"2017","unstructured":"Smith LT. Cytokine release syndrome: inpatient care for side effects of CAR T-cell therapy. Number 2\/April 2017. 2017;21(2):29\u201334.","journal-title":"Number 2\/April 2017"},{"key":"2923_CR262","doi-asserted-by":"publisher","first-page":"323","DOI":"10.2147\/TCRM.S150524","volume":"28","author":"LL Riegler","year":"2019","unstructured":"Riegler LL, Jones GP, Lee DW. Current approaches in the grading and management of cytokine release syndrome after chimeric antigen receptor T-cell therapy. Ther Clin Risk Manag. 2019;28:323\u201335.","journal-title":"Ther Clin Risk Manag"},{"issue":"11","key":"2923_CR263","volume":"28","author":"EL Siegler","year":"2020","unstructured":"Siegler EL, Kenderian SS. Neurotoxicity and cytokine release syndrome after chimeric antigen receptor T-cell therapy: insights into mechanisms and novel therapies. Front Immunol. 2020;28(11): 550628.","journal-title":"Front Immunol"},{"issue":"2","key":"2923_CR264","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1038\/s41577-021-00547-6","volume":"22","author":"EC Morris","year":"2022","unstructured":"Morris EC, Neelapu SS, Giavridis T, Sadelain M. Cytokine release syndrome and associated neurotoxicity in cancer immunotherapy. Nat Rev Immunol. 2022;22(2):85\u201396.","journal-title":"Nat Rev Immunol"},{"issue":"11","key":"2923_CR265","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2020.577027","volume":"16","author":"J Gust","year":"2020","unstructured":"Gust J, Ponce R, Liles WC, Turtle CJ. Cytokines in CAR T-cell\u2013associated neurotoxicity. Front Immunol. 2020;16(11): 577027.","journal-title":"Front Immunol"},{"key":"2923_CR266","doi-asserted-by":"publisher","first-page":"2386187","DOI":"10.1155\/2018\/2386187","volume":"2018","author":"S Sun","year":"2018","unstructured":"Sun S, Hao H, Yang G, Zhang Y, Fu Y. Immunotherapy with CAR-Modified T Cells: toxicities and overcoming strategies. J Immunol Res. 2018;2018:2386187. https:\/\/doi.org\/10.1155\/2018\/2386187.","journal-title":"J Immunol Res"},{"key":"2923_CR267","first-page":"3","volume":"1","author":"CL Bonifant","year":"2016","unstructured":"Bonifant CL, Jackson HJ, Brentjens RJ, Curran KJ. Toxicity and management in CAR T-cell therapy. Mol Therapy-Oncolyt. 2016;1:3.","journal-title":"Mol Therapy-Oncolyt"},{"key":"2923_CR268","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/s11912-020-00935-6","volume":"22","author":"K Landry","year":"2020","unstructured":"Landry K, Thomas AA. Neurological complications of CAR T-cell therapy. Curr Oncol Rep. 2020;22:1\u20138.","journal-title":"Curr Oncol Rep"},{"issue":"4","key":"2923_CR269","doi-asserted-by":"publisher","first-page":"1544","DOI":"10.1007\/s00415-020-10237-3","volume":"268","author":"EC Tallantyre","year":"2021","unstructured":"Tallantyre EC, Evans NA, Parry-Jones J, Morgan MP, Jones CH, Ingram W. Neurological updates: neurological complications of CAR-T therapy. J Neurol. 2021;268(4):1544\u201354.","journal-title":"J Neurol"},{"issue":"2","key":"2923_CR270","first-page":"13","volume":"23","author":"K Anderson","year":"2019","unstructured":"Anderson K. Associated toxicities: assessment and management related to CAR T-cell therapy. Number 2\/April 2019. 2019;23(2):13\u20139.","journal-title":"Number 2\/April 2019"},{"key":"2923_CR271","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1007\/s11899-023-00687-7","volume":"18","author":"KL Chohan","year":"2023","unstructured":"Chohan KL, Siegler EL, Kenderian SS. CAR-T-Cell therapy: the efficacy and toxicity balance. Curr Hematol Malig Rep. 2023;18:9\u201318. https:\/\/doi.org\/10.1007\/s11899-023-00687-7.","journal-title":"Curr Hematol Malig Rep"},{"issue":"6","key":"2923_CR272","doi-asserted-by":"publisher","first-page":"359","DOI":"10.1038\/s41571-023-00754-1","volume":"20","author":"KM Cappell","year":"2023","unstructured":"Cappell KM, Kochenderfer JN. Long-term outcomes following CAR T-cell therapy: what we know thus far. Nat Rev Clin Oncol. 2023;20(6):359\u201371.","journal-title":"Nat Rev Clin Oncol"},{"issue":"1","key":"2923_CR273","doi-asserted-by":"publisher","first-page":"34","DOI":"10.1016\/j.annonc.2020.10.478","volume":"32","author":"ML Schubert","year":"2021","unstructured":"Schubert ML, Schmitt M, Wang L, Ramos CA, Jordan K, M\u00fcller-Tidow C, Dreger P. Side-effect management of chimeric antigen receptor (CAR) T-cell therapy. Ann Oncol. 2021;32(1):34\u201348.","journal-title":"Ann Oncol"},{"issue":"21","key":"2923_CR274","doi-asserted-by":"publisher","first-page":"8305","DOI":"10.3390\/ijms21218305","volume":"21","author":"N Hosseinkhani","year":"2020","unstructured":"Hosseinkhani N, Derakhshani A, Kooshkaki O, Abdoli Shadbad M, Hajiasgharzadeh K, Baghbanzadeh A, Safarpour H, Mokhtarzadeh A, Brunetti O, Yue SC, Silvestris N. Immune checkpoints and CAR-T cells: the pioneers in future cancer therapies? Int J Mol Sci. 2020;21(21):8305.","journal-title":"Int J Mol Sci"},{"issue":"12","key":"2923_CR275","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2021.744823","volume":"6","author":"H Lin","year":"2021","unstructured":"Lin H, Cheng J, Mu W, Zhou J, Zhu L. Advances in universal CAR-T-cell therapy. Front Immunol. 2021;6(12): 744823.","journal-title":"Front Immunol"},{"issue":"2","key":"2923_CR276","doi-asserted-by":"publisher","DOI":"10.1097\/HS9.0000000000000191","volume":"3","author":"JG Borrega","year":"2019","unstructured":"Borrega JG, G\u00f6del P, R\u00fcger MA, Onur \u00d6A, Shimabukuro-Vornhagen A, Kochanek M, B\u00f6ll B. In the eye of the storm: immune-mediated toxicities associated with CAR-T-cell therapy. Hemasphere. 2019;3(2): e191.","journal-title":"Hemasphere"},{"issue":"1","key":"2923_CR277","doi-asserted-by":"publisher","first-page":"98","DOI":"10.1186\/s12885-021-09102-x","volume":"22","author":"W Luo","year":"2022","unstructured":"Luo W, Li C, Zhang Y, Du M, Kou H, Lu C, Mei H, Hu Y. Adverse effects in hematologic malignancies treated with chimeric antigen receptor (CAR) T-cell therapy: a systematic review and Meta-analysis. BMC Cancer. 2022;22(1):98.","journal-title":"BMC Cancer"},{"key":"2923_CR278","unstructured":"Buitrago J, Adkins S, Hawkins M, Iyamu K, van Oort T. (2019) Adult Survivorship: Considerations following CAR T-cell therapy. Clin J Oncol Nurs 23(2)"},{"issue":"11","key":"2923_CR279","doi-asserted-by":"publisher","first-page":"3445","DOI":"10.3390\/cancers12113445","volume":"12","author":"O Penack","year":"2020","unstructured":"Penack O, Koenecke C. Complications after CD19+ CAR T-cell therapy. Cancers. 2020;12(11):3445.","journal-title":"Cancers"},{"key":"2923_CR280","doi-asserted-by":"publisher","first-page":"363","DOI":"10.1038\/s41571-020-00456-y","volume":"18","author":"H Shalabi","year":"2021","unstructured":"Shalabi H, Gust J, Taraseviciute A, et al. Beyond the storm \u2014 subacute toxicities and late effects in children receiving CAR T cells. Nat Rev Clin Oncol. 2021;18:363\u201378. https:\/\/doi.org\/10.1038\/s41571-020-00456-y.","journal-title":"Nat Rev Clin Oncol"},{"key":"2923_CR281","doi-asserted-by":"publisher","DOI":"10.1002\/ctd2.283","author":"P Bende","year":"2024","unstructured":"Bende P. Sculpting nursing resilience: transforming lives, nurturing ethics in chimeric antigen receptor T-cell therapy. Clin Translat Discov. 2024. https:\/\/doi.org\/10.1002\/ctd2.283.","journal-title":"Clin Translat Discov"},{"key":"2923_CR282","doi-asserted-by":"publisher","DOI":"10.1111\/ejh.14123","author":"I Wang","year":"2023","unstructured":"Wang I, Mei H. Chimeric antigen receptor T-cell therapy, where are we now and where are we heading for. Eur J Haematol. 2023. https:\/\/doi.org\/10.1111\/ejh.14123.","journal-title":"Eur J Haematol"},{"key":"2923_CR283","doi-asserted-by":"publisher","first-page":"246","DOI":"10.1016\/j.jconrel.2019.12.047","volume":"319","author":"TR Abreu","year":"2020","unstructured":"Abreu TR, Fonseca NA, Gon\u00e7alves N, Moreira JN. Current challenges and emerging opportunities of CAR-T cell therapies. J Control Rel. 2020;319:246\u201361.","journal-title":"J Control Rel"},{"key":"2923_CR284","doi-asserted-by":"publisher","first-page":"566","DOI":"10.1038\/nrc.2016.97","volume":"16","author":"AD Fesnak","year":"2016","unstructured":"Fesnak AD, June CH, Levine BL. Engineered T cells: the promise and challenges of cancer immunotherapy. Nat Rev Cancer. 2016;16:566\u201381. https:\/\/doi.org\/10.1038\/nrc.2016.97.","journal-title":"Nat Rev Cancer"},{"key":"2923_CR285","doi-asserted-by":"publisher","first-page":"1183","DOI":"10.15252\/emmm.201607485","volume":"9","author":"J Hartmann","year":"2017","unstructured":"Hartmann J, Sch\u00fc\u00dfler-Lenz M, Bondanza A, Buchholz CJ. Clinical development of CAR T cells\u2014Challenges and opportunities in translating innovative treatment concepts. EMBO Mol Med. 2017;9:1183\u201397. https:\/\/doi.org\/10.15252\/emmm.201607485.","journal-title":"EMBO Mol Med"},{"key":"2923_CR286","doi-asserted-by":"publisher","first-page":"81","DOI":"10.1186\/s13287-020-02128-1","volume":"12","author":"F Marofi","year":"2021","unstructured":"Marofi F, Motavalli R, Safonov VA, Thangavelu L, Yumashev AV, Alexander M, Shomali N, Chartrand MS, Pathak Y, Jarahian M, et al. CAR T cells in solid tumors: challenges and opportunities. Stem Cell Res Ther. 2021;12:81. https:\/\/doi.org\/10.1186\/s13287-020-02128-1.","journal-title":"Stem Cell Res Ther"},{"issue":"1","key":"2923_CR287","doi-asserted-by":"publisher","first-page":"28","DOI":"10.1097\/PPO.0000000000000636","volume":"29","author":"SK Brookens","year":"2023","unstructured":"Brookens SK, Posey AD Jr. Chimeric antigen receptor T-Cell therapy: current perspective on T-Cell\u2013Intrinsic, T-Cell\u2013extrinsic, and therapeutic limitations. Cancer J. 2023;29(1):28\u201333.","journal-title":"Cancer J"},{"key":"2923_CR288","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1038\/s41408-021-00459-7","volume":"11","author":"RC Sterner","year":"2021","unstructured":"Sterner RC, Sterner RM. CAR-T-Cell therapy: current limitations and potential strategies. Blood Cancer J. 2021;11:69. https:\/\/doi.org\/10.1038\/s41408-021-00459-7.","journal-title":"Blood Cancer J"},{"issue":"11","key":"2923_CR289","volume":"5","author":"E Garc\u00eda-Guerrero","year":"2020","unstructured":"Garc\u00eda-Guerrero E, Sierro-Mart\u00ednez B, P\u00e9rez-Sim\u00f3n JA. Overcoming chimeric antigen receptor (CAR) modified T-cell therapy limitations in multiple myeloma. Front Immunol. 2020;5(11): 539708.","journal-title":"Front Immunol"},{"issue":"2","key":"2923_CR290","doi-asserted-by":"publisher","first-page":"813","DOI":"10.1016\/j.ijpharm.2017.07.075","volume":"532","author":"H Jakobczyk","year":"2017","unstructured":"Jakobczyk H, Sciortino F, Chevance S, Gauffre F, Troadec MB. Promises and limitations of nanoparticles in the era of cell therapy: Example with CD19-targeting chimeric antigen receptor (CAR)-modified T cells. Int J Pharm. 2017;532(2):813\u201324.","journal-title":"Int J Pharm"},{"issue":"5","key":"2923_CR291","doi-asserted-by":"publisher","first-page":"472","DOI":"10.3390\/cells8050472","volume":"8","author":"S Stoiber","year":"2019","unstructured":"Stoiber S, Cadilha BL, Benmebarek MR, Lesch S, Endres S, Kobold S. Limitations in the design of chimeric antigen receptors for cancer therapy. Cells. 2019;8(5):472.","journal-title":"Cells"},{"issue":"2","key":"2923_CR292","doi-asserted-by":"publisher","first-page":"98","DOI":"10.1016\/j.tmrv.2019.01.005","volume":"33","author":"EJ Grigor","year":"2019","unstructured":"Grigor EJ, Fergusson D, Kekre N, Montroy J, Atkins H, Seftel MD, Daugaard M, Presseau J, Thavorn K, Hutton B, Holt RA. Risks and benefits of chimeric antigen receptor T-cell (CAR-T) therapy in cancer: a systematic review and meta-analysis. Transfus Med Rev. 2019;33(2):98\u2013110.","journal-title":"Transfus Med Rev"},{"key":"2923_CR293","doi-asserted-by":"publisher","first-page":"95","DOI":"10.1002\/hon.2591","volume":"37","author":"D Sermer","year":"2019","unstructured":"Sermer D, Brentjens R. CAR T-cell therapy: full speed ahead. Hematol Oncol. 2019;37:95\u2013100.","journal-title":"Hematol Oncol"},{"key":"2923_CR294","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2022.968395","volume":"13","author":"V To","year":"2022","unstructured":"To V, Evtimov VJ, Jenkin G, Pupovac A, Trounson AO, Boyd RL. CAR-T-cell development for Cutaneous T-cell Lymphoma: current limitations and potential treatment strategies. Front Immunol. 2022;13: 968395. https:\/\/doi.org\/10.3389\/fimmu.2022.968395.","journal-title":"Front Immunol"},{"key":"2923_CR295","doi-asserted-by":"publisher","first-page":"495","DOI":"10.1007\/s13402-021-00593-1","volume":"44","author":"M Akhoundi","year":"2021","unstructured":"Akhoundi M, Mohammadi M, Sahraei SS, et al. CAR T-cell therapy as a promising approach in cancer immunotherapy: challenges and opportunities. Cell Oncol. 2021;44:495\u2013523. https:\/\/doi.org\/10.1007\/s13402-021-00593-1.","journal-title":"Cell Oncol"},{"key":"2923_CR296","first-page":"11145","volume":"15","author":"A Tahavvori","year":"2022","unstructured":"Tahavvori A, Alizadeh F, Mousavian A, Namazi MJ, Tadi MJ, Baghbani-Varjavi M, Doustar N, Tahernia H, Khalaji A, Jabraeilipour A. Achievements, challenges, and limitations of Car-T-Cell therapy in cancer treatment, a comprehensive review. J Pharm Neg Result. 2022;15:11145\u201352.","journal-title":"J Pharm Neg Result"},{"issue":"5","key":"2923_CR297","doi-asserted-by":"publisher","first-page":"532","DOI":"10.1007\/s12185-020-02923-9","volume":"114","author":"S Lundh","year":"2021","unstructured":"Lundh S, Maji S, Melenhorst JJ. Next-generation CAR T cells to overcome current drawbacks. Int J Hematol. 2021;114(5):532\u201343.","journal-title":"Int J Hematol"},{"issue":"5","key":"2923_CR298","doi-asserted-by":"publisher","first-page":"503","DOI":"10.1080\/14712598.2020.1738378","volume":"20","author":"S Ramakrishna","year":"2020","unstructured":"Ramakrishna S, Barsan V, Mackall C. Prospects and challenges for use of CAR T-cell therapies in solid tumors. Expert Opin Biol Ther. 2020;20(5):503\u201316.","journal-title":"Expert Opin Biol Ther"},{"issue":"12","key":"2923_CR299","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2021.640082","volume":"3","author":"D Mart\u00ednez Bedoya","year":"2021","unstructured":"Mart\u00ednez Bedoya D, Dutoit V, Migliorini D. Allogeneic CAR T cells: an alternative to overcome challenges of CAR T-cell therapy in glioblastoma. Front Immunol. 2021;3(12): 640082.","journal-title":"Front Immunol"},{"key":"2923_CR300","doi-asserted-by":"publisher","first-page":"2348","DOI":"10.1182\/bloodadvances.2017009928","volume":"1","author":"YT Png","year":"2017","unstructured":"Png YT, Vinanica N, Kamiya T, Shimasaki N, Coustan-Smith E, Campana D. Blockade of CD7 Expression in T Cells for Effective Chimeric Antigen Receptor Targeting of T-Cell Malignancies. Blood Adv. 2017;1:2348\u201360. https:\/\/doi.org\/10.1182\/bloodadvances.2017009928.","journal-title":"Blood Adv"},{"key":"2923_CR301","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1158\/2326-6066.CIR-13-0006","volume":"1","author":"MV Maus","year":"2013","unstructured":"Maus MV, Haas AR, Beatty GL, et al. T cells expressing chimeric antigen receptors can cause anaphylaxis in humans. Cancer Immunol Res. 2013;1:26\u201331.","journal-title":"Cancer Immunol Res"},{"issue":"3","key":"2923_CR302","doi-asserted-by":"publisher","first-page":"147","DOI":"10.1038\/s41571-019-0297-y","volume":"17","author":"S Rafiq","year":"2020","unstructured":"Rafiq S, Hackett CS, Brentjens RJ. Engineering strategies to overcome the current roadblocks in CAR T-cell therapy. Nat Rev Clin Oncol. 2020;17(3):147\u201367.","journal-title":"Nat Rev Clin Oncol"},{"issue":"12","key":"2923_CR303","doi-asserted-by":"publisher","first-page":"896","DOI":"10.1007\/s13238-017-0400-z","volume":"8","author":"Z Wang","year":"2017","unstructured":"Wang Z, Guo Y, Han W. Current status and perspectives of chimeric antigen receptor modified T cells for cancer treatment. Protein Cell. 2017;8(12):896\u2013925.","journal-title":"Protein Cell"},{"key":"2923_CR304","doi-asserted-by":"publisher","first-page":"3321","DOI":"10.1182\/blood-2016-04-703751","volume":"127","author":"JN Brudno","year":"2016","unstructured":"Brudno JN, Kochenderfer JN. Toxicities of chimeric antigen receptor T cells: recognition and management. Blood. 2016;127:3321\u201330.","journal-title":"Blood"},{"key":"2923_CR305","doi-asserted-by":"publisher","first-page":"E2068","DOI":"10.1073\/pnas.1716266115","volume":"115","author":"AJ Davenport","year":"2018","unstructured":"Davenport AJ, Cross RS, Watson KA, Liao Y, Shi W, Prince HM, Beavis PA, Trapani JA, Kershaw MH, Ritchie DS, et al. Chimeric antigen receptor T cells form nonclassical and potent immune synapses driving rapid cytotoxicity. Proc Natl Acad Sci USA. 2018;115:E2068\u201376. https:\/\/doi.org\/10.1073\/pnas.1716266115.","journal-title":"Proc Natl Acad Sci USA"},{"key":"2923_CR306","doi-asserted-by":"publisher","first-page":"2561","DOI":"10.1056\/NEJMoa1610497","volume":"375","author":"CE Brown","year":"2016","unstructured":"Brown CE, Alizadeh D, Starr R, Weng L, Wagner JR, Naranjo A, Ostberg JR, Blanchard MS, Kilpatrick J, Simpson J, et al. Regression of glioblastoma after chimeric antigen receptor T-Cell therapy. N Engl J Med. 2016;375:2561\u20139. https:\/\/doi.org\/10.1056\/NEJMoa1610497.","journal-title":"N Engl J Med"},{"issue":"2","key":"2923_CR307","doi-asserted-by":"publisher","DOI":"10.1097\/HS9.0000000000000188","volume":"3","author":"S Charrot","year":"2019","unstructured":"Charrot S, Hallam S. CAR-T cells: future perspectives. Hemasphere. 2019;3(2): e188.","journal-title":"Hemasphere"},{"key":"2923_CR308","doi-asserted-by":"publisher","first-page":"619","DOI":"10.1007\/s12015-019-09901-7","volume":"15","author":"S Tahmasebi","year":"2019","unstructured":"Tahmasebi S, Elahi R, Esmaeilzadeh A. Solid tumors challenges and new insights of CAR T-cell engineering. Stem cell Rev Rep. 2019;15:619\u201336.","journal-title":"Stem cell Rev Rep"},{"issue":"5","key":"2923_CR309","doi-asserted-by":"publisher","first-page":"486","DOI":"10.4111\/icu.20220103","volume":"63","author":"TJ Kim","year":"2022","unstructured":"Kim TJ, Lee YH, Koo KC. Current and future perspectives on CAR-T-cell therapy for renal cell carcinoma: a comprehensive review. Investig Clin Urol. 2022;63(5):486\u201398. https:\/\/doi.org\/10.4111\/icu.20220103. (PMID:36067994;PMCID:PMC9448669).","journal-title":"Investig Clin Urol"},{"issue":"4","key":"2923_CR310","doi-asserted-by":"publisher","first-page":"403","DOI":"10.1002\/1873-3468.14270","volume":"596","author":"R Abrantes","year":"2022","unstructured":"Abrantes R, Duarte HO, Gomes C, W\u00e4lchli S, Reis CA. CAR-Ts: new perspectives in cancer therapy. FEBS Lett. 2022;596(4):403\u201316.","journal-title":"FEBS Lett"},{"key":"2923_CR311","doi-asserted-by":"publisher","first-page":"1062","DOI":"10.3390\/healthcare9081062","volume":"9","author":"NA Ivica","year":"2021","unstructured":"Ivica NA, Young CM. Tracking the Car-t revolution: analysis of clinical trials of CAR-T and Tcr-t therapies for the treatment of cancer (1997\u20132020). Healthcare. 2021;9:1062. https:\/\/doi.org\/10.3390\/healthcare9081062.","journal-title":"Healthcare"},{"issue":"12","key":"2923_CR312","doi-asserted-by":"publisher","first-page":"2548","DOI":"10.7150\/ijbs.34213","volume":"15","author":"S Ma","year":"2019","unstructured":"Ma S, Li X, Wang X, Cheng L, Li Z, Zhang C, Ye Z, Qian Q. Current progress in CAR-T-cell therapy for solid tumors. Int J Biol Sci. 2019;15(12):2548.","journal-title":"Int J Biol Sci"},{"key":"2923_CR313","doi-asserted-by":"publisher","first-page":"1403","DOI":"10.3390\/cancers14061403","volume":"14","author":"A Nguyen","year":"2022","unstructured":"Nguyen A, Johanning G, Shi Y. Emerging novel combined CAR-T-Cell therapies. Cancers. 2022;14:1403. https:\/\/doi.org\/10.3390\/cancers14061403.","journal-title":"Cancers"},{"key":"2923_CR314","doi-asserted-by":"publisher","DOI":"10.1016\/j.ebiom.2020.102931","volume":"58","author":"J Jayaraman","year":"2020","unstructured":"Jayaraman J, Mellody MP, Hou AJ, et al. CAR-T design: Elements and their synergistic function. EBioMedicine. 2020;58: 102931. https:\/\/doi.org\/10.1016\/j.ebiom.2020.102931.","journal-title":"EBioMedicine"},{"issue":"12","key":"2923_CR315","first-page":"833","volume":"20","author":"S Krishnamurthy","year":"2021","unstructured":"Krishnamurthy S, Wohlford-Lenane C, Langel SN, et al. Engineered cell therapies for cancer and beyond: from the bench to the clinic. Nat Rev Drug Discov. 2021;20(12):833\u201352.","journal-title":"Nat Rev Drug Discov"},{"issue":"6576","key":"2923_CR316","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1126\/science.abm0594","volume":"375","author":"JG Rurik","year":"2022","unstructured":"Rurik JG, Tomb\u00e1cz I, Yadegari A, et al. CAR T cells produced in vivo to treat cardiac injury. Science. 2022;375(6576):91\u20136.","journal-title":"Science"},{"key":"2923_CR317","volume":"12","author":"L Lin","year":"2021","unstructured":"Lin L, Zhang J, Dai L, Gao H. CAR-NK cells: a promising cellular immunotherapy for cancer. Front Immunol. 2021;12: 626543.","journal-title":"Front Immunol"},{"issue":"11","key":"2923_CR318","first-page":"1292","volume":"38","author":"L Zhang","year":"2020","unstructured":"Zhang L, Tian L, Dai X, et al. Pluripotent stem cell\u2013derived CAR-macrophage cells with antitumor potential in solid tumors. Nat Biotechnol. 2020;38(11):1292\u2013300.","journal-title":"Nat Biotechnol"},{"issue":"7","key":"2923_CR319","first-page":"616","volume":"15","author":"F Lei","year":"2020","unstructured":"Lei F, Wang Y, Luo L, et al. In vivo programming of tumor-specific T cells using synthetic DNA nanocarriers. Nat Nanotechnol. 2020;15(7):616\u201322.","journal-title":"Nat Nanotechnol"},{"issue":"8","key":"2923_CR320","first-page":"555","volume":"18","author":"KT Roybal","year":"2018","unstructured":"Roybal KT, Williams JZ, Morsut L, et al. Engineering T cells with synthetic biology. Nat Rev Immunol. 2018;18(8):555\u201365.","journal-title":"Nat Rev Immunol"},{"issue":"4","key":"2923_CR321","doi-asserted-by":"publisher","first-page":"539","DOI":"10.1016\/j.apsb.2018.03.001","volume":"8","author":"Z Zhao","year":"2018","unstructured":"Zhao Z, Chen Y, Francisco NM, Zhang Y, Wu M. The application of CAR-T-cell therapy in hematological malignancies: advantages and challenges. Acta Pharmaceut Sinica B. 2018;8(4):539\u201351.","journal-title":"Acta Pharmaceut Sinica B"}],"container-title":["Medical Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12032-025-02923-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12032-025-02923-x\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12032-025-02923-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,8]],"date-time":"2025-09-08T00:36:51Z","timestamp":1757291811000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12032-025-02923-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,7,25]]},"references-count":321,"journal-issue":{"issue":"9","published-online":{"date-parts":[[2025,9]]}},"alternative-id":["2923"],"URL":"https:\/\/doi.org\/10.1007\/s12032-025-02923-x","relation":{},"ISSN":["1559-131X"],"issn-type":[{"value":"1559-131X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,7,25]]},"assertion":[{"value":"8 April 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 July 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 July 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"Not applicable.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Informed consent"}},{"value":"None.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Prior publication"}},{"value":"None.","order":6,"name":"Ethics","group":{"name":"EthicsHeading","label":"Sources of Support"}}],"article-number":"376"}}